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Adverse drug reactions (ADRs) cause a global and substantial burden accounting for 
considerable mortality, morbidity and extra costs. In the United States, over 770,000 ADR 
related injures or deaths occur each year in hospitals, which may cost up to $5.6 million each 
year per hospital. Unanticipated ADRs may occur after a drug has been approved due to its use 
or prolonged use on large, diverse populations. Therefore, the post-marketing surveillance of 
drugs is essential for generating more complete drug safety profiles and for providing a decision 
making tool to help governmental drug administration agencies take an action on the marketed 
drugs. Analysis of spontaneous reports of suspected ADRs has traditionally served as a valuable 
tool in pharmacovigilance. However, because of well-known limitations of spontaneous reports, 
observational healthcare data, such as electronic health records (EHRs) and administrative claims 
data, are starting to be used to complement the spontaneous reporting system. Synthesizing ADR 
evidence from multiple data sources has been conducted by human experts on an at hoc basis. 
However, the amount of data from both spontaneous reporting systems (SRSs) and observational 
healthcare databases is growing exponentially. The revolution in the ability of machines to 
access, process, and mine databases, making it advantageous to develop an automatic system to 
obtain integrated evidence by combining them.    
  
Towards this goal, this dissertation proposes a framework consisting of three components that 
generates signal scores based on data an EHR system and of an SRS system, and then integrates 
two signal scores into a composite one. The first component is a data-driven and regression-
based method that aims to alleviate confounding effect and detect ADR based on EHRs. The 
results demonstrate that this component achieves comparable or slightly higher accuracy than 
those trained with experts and existing automatic methods. The second component is also a data-
driven and regression-based method that aims to reduce the effect of confounding by co-
medication and confounding by indication using primary suspected, secondary suspected, 
concomitant medications and indications on the basis of a SRS. This study demonstrates that it 
could accomplish comparable or slightly better accuracy than the cutting edge algorithm Gamma 
Poisson Shrinkage (GPS), which uses primary suspected medications only. The third component 
is a computational integration method that normalizes signal scores from each data source and 
integrates them into a composite signal score. The results achieved by the method demonstrate 
that the combined ADR evidence achieve better accuracy of drug-ADR detection than individual 
systems based on either an SRS or an EHR. Furthermore, component three is explored as a tool 
to assist clinical assessors in pharmacovigilance practice.  
The research presented in this dissertation has produced several novel insights and provided new 
solutions towards the challenging problem of pharmacovigilance. The method of reducing 
confounding effect can be generalizable to other EHR systems and the method for integrating 
ADR evidence can be generalizable to include other data sources. In conclusion, this dissertation 
develops a method to reduce confounding effect in both EHRs and SRSs, and a combined system 
to synthesize evidence, which could potentially unveil drug safety profiles and novel adverse 
events in a timely fashion.
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CHAPTER 1 Introduction 
1.1 Problem and Significance  
It is perhaps a fundamental truth in medicine that there is no medication that is without risk 
(Coloma 2012). Even with the most rigorous efforts in drug approval and regulation, 
unanticipated adverse drug reactions (ADRs) may occur. In the 1960s, the thalidomide disaster 
affected nearly 10,000 people around the globe. Post-marketing surveillance, also referred to as 
pharmacovigilance, has drawn a great deal of attention from the public ever since.  
The burden of ADRs worldwide is high, accounting for considerable morbidity, mortality, and 
extra costs. The Institute of Medicine reported in January of 2000 that an estimated 7,000 deaths 
per year occur due to ADRs (Kohn, Corrigan et al. 2000). Another study conducted based on 
hospitalized patient populations estimate that 6.7% of hospitalized patients had a serious adverse 
drug reaction with a mortality rate of 0.32% (Lazarou, Pomeranz et al. 1998).  Also, it was 
estimated that over 350,000 ADRs occur in U.S. nursing homes each year (Gurwitz, Field et al. 
2000). Meanwhile, one estimate of the cost of drug-related morbidity and mortality is $136 
billion annually, which is more than the total cost of cardiovascular or diabetic care in the United 
States (Johnson and Bootman 1995). In addition, studies indicated that national hospital expenses 
to treat patients who suffer ADRs are estimated between $1.56 and $5.6 billion annually (Bates, 
Cullen et al. 1995, Bates, Spell et al. 1997, Raschke, Gollihare et al. 1998, Thomas, Studdert et 




Randomized controlled trials (RCTs) are considered to be the “gold standard” for determining a 
cause-and-effect relationship between a medication and an outcome, however, these trials are 
rarely large enough to accurately measure infrequent adverse outcomes (Black 1996). Once 
drugs are on the market, they are used on a much larger and more diverse population, often with 
prolonged periods and sometimes with a wider range of therapeutic indications (Amery 1999, 
Berlin, Glasser et al. 2008), and consequently unanticipated ADRs may occur. Therefore, post-
marketing surveillance of approved drugs is essential for generating more complete drug safety 
profiles. Extending resources to observational data and methods represent a set of 
complementary approaches that could potentially augment ADR detection (Olsson 1998, Ahmad 
2003).  
Post-marketing drug safety surveillance has traditionally been conducted by systematic manual 
review of reports of suspected ADRs in spontaneous reporting systems (SRSs), which are mainly 
described by healthcare professionals, consumers, and pharmaceutical manufacturers (Hauben, 
Madigan et al. 2005).  It is impractical to manually review the reports due to a large amount of 
reports as well as the continuous influx of new drugs. For the past decades, various automatic 
signal detection methods have been developed on the basis of SRSs to supplement qualitative 
clinical evaluation (van Puijenbroek, Bate et al. 2002). The success of current pharmacovigilance 
systems, however, is hampered by limitations inherent in the SRS databases, such as 
underreporting and the pitfalls of automatic signal detection methods, such as not appropriately 
dealing with confounding. It has shown that ADRs may be detected and acted upon too late 
(Topol 2004). The withdrawal of rofecoxib, together with other significant safety issues, when 
millions of persons have already been exposed, have stimulated initiatives worldwide to explore 
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new methods to facilitate earlier detection of novel ADRs. A recent resource involves mining of 
observational healthcare data, including routinely-collected, longitudinal electronic healthcare 
records (EHRs) and longitudinal billing oriented claims data. Different research groups have 
carried out considerable studies on the basis of large-scale EHRs or claims data and have 
demonstrated that observational healthcare database can augment existing pharmacovigilance 
systems  (Coloma 2012).    
Given the relative maturity of the pharmacovigilance based on SRS, the rapid development of 
ADR detection on the basis of observational healthcare data, and vast improvements in 
computing capabilities, the time is ripe to develop methods for integrating ADR evidence from 
two or more resources. Towards this goal, we develop a method to synergistically combine ADR 
signals mined from complementary data sources and demonstrate the potential of the method 
using a published reference standards. The quality of signals generated by the combination 
system depends on the quality of their counterparts produced by each individual source. It is well 
known that confounding effect is one of the most challenging problems leading to high false 
positive rates, therefore we developed two methods for controlling complex confounding effect 
in the EHR and SRS,  
1.3 Research Hypotheses 
This dissertation has three aims. First, to develop novel methods for alleviating confounding 
effect in observational health data, such as EHR, so that EHR-based pharmacovigilance method 
can be improved. Second, to develop novel methods for reducing confounding by indication and 
concomitant medications based on SRSs. Third, to develop novel methods that leverage ADR 
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evidence from multiple databases synergistically so that the combined method could detect 
ADRs more effectively than the individual data sources.    
Specifically: 
1. Detecting ADR signals from the observational healthcare databases, such as a single facility 
EHR, is challenging due to the existence of complex confounding effect that leads to the high 
false positive rate. The proposed data-driven and regression-based method could effectively 
reduce the confounding issue resulting in the improvement of ADR detection accuracy compared 
with other existing methods.  
2. Leveraging information of concomitant medications and indications in FDA adverse event 
reporting system (FAERS) can improve ADR detection performance compared with the 
traditional measurements produced by disproportionality analyses, which are solely based on 
information of primary suspected medications. 
3. Computationally integrating ADR evidence generated by the FDA adverse event reporting 
system (FAERS) and observational healthcare data can result in a more accurate and sensitive 
ADR detection system than systems based on individual sources. 
1.4 Thesis Overview 
In this dissertation, we develop an integrative system synthesizing ADR evidence from multiple 
heterogeneous databases, which includes the following components: (1) a data-driven and 
regression-based method for reducing confounding effect and therefore improving ADR signal 
detection in NYP/CUMC EHR; (2) a data-driven and regression-based method leveraging 
primary suspected medications, concomitant medications and indications, and alleviating 
confounding effect in FAERS. (3) a computational method to automatically integrate evidence 
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on the basis of data from observational healthcare data and FAERS, which can serve as a tool for 
clinical assessors in actual pharmacovigilance practice.  
Chapter 2 contains background material associated with pharmacovigilance, including a) a 
survey of current databases, algorithms and reference standards used for post-marketing 
surveillance of drug safety, b) a review of relevant studies, and c) a summary of related 
techniques including natural language processing and biomedical terminologies. 
Chapter 3 describes a data driven method to detect ADR signals using primarily inpatient data 
associated with a single hospital visit as well as evaluation of the method based on a reference 
standard consisting of two serious ADRs and drugs known to cause them. The method includes 
the following five steps: 1) data collection and preparation; 2) identification of candidate drug 
safety signals; 3) identification of confounders for specific medications; 4) estimation of the 
medication–ADR associations adjusting for potential confounders; 5) determination of the 
adjusted medication-ADR signals. The evaluation involves a reference standard consisted of 
1,055 known positive drugs for two serious ADRs, and focuses on the precision of detecting 
known drug-ADR signals and on comparison with other existing methods using the precision as 
an assessment metric. 
Chapter 4 presents a study of the effect of data characteristics on ADR detection methods when 
the resource is FAERS. In this work, we explore the use of concomitant medication and 
indication information in addition to primary suspected information to improve the performance 
of ADR detection. For evaluation, a reference standard comprising 165 positive and 234 negative 
drug-ADR pairs is utilized and the major assessment metric is the area under a receiver operating 
characteristic curve (AUC). 
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Chapter 5 develops a computational method to combine signals from observational healthcare 
databases and FAERS. In this work, we conduct three experiments involving combining FAERS 
with a single facility small-scale EHR, a larger-scale network-based EHR, and a much larger-
scale healthcare claims database. The evaluation uses a reference standard comprising 165 
positive and 234 negative drug-ADR pairs, and focuses on the AUC. Furthermore, we 
demonstrate that the proposed system can serve as a tool for synthesizing ADR evidence under 
two different scenarios that generally occur in actual pharmacovigilance practice, namely when 
two data sources provide either consistent or inconsistent information about particular drug-ADR 
pairs.  
Chapter 6 summarizes and discusses the contributions and significance of the overall framework 
for reducing confounding effect, generating ADR signals and integrating ADR evidence, and 
presents the limitations, future work and overall conclusions.  
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CHAPTER 2 Background 
In this chapter, we provide an overview of the key data sources for pharmacovigilance, survey 
methods that are state of the art, describe reference standards centering on these data. We also 
review relevant work concerning synthesizing evidence from multiple data sources, and describe 
related techniques for conducting studies discussed in this thesis.  
2.1 Overview 
Pharmacovigilance (PhV), also referred to as drug safety surveillance, has been defined as “the 
pharmacological science relating to the detection, assessment, understanding and prevention of 
adverse effects, particularly long term and short term side effects of medicines”. The collection 
of PhV information starts at the pre-approval stage, such as phase I-III of clinical trials, and 
continues in the post-approval stage and throughout a drug’s life on the market. Typical 
databases used in the post-marketing stages include spontaneous reporting systems, 
observational healthcare databases and prescription event monitoring databases. More recently, 
biomedical literature and data produced by the Internet have caught researchers’ attention. With 
a rapid increase of the data size, automatic methods to deal with data and generate ADR signals 
have been studied and developed.    
2.2 Data source used in support of Pharmacovigilance 
2.2.1 Spontaneous reporting systems 
In the aftermath of the thalidomide tragedy in the late1960s, the United States Food and Drug 
Administration (FDA), the World Health Organization (WHO), and the European Agency for the 
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Evaluation of Medical Products (EMEA) and other governmental drug administration agencies 
independently set up spontaneous reporting systems (SRSs) designated for the collection and 
subsequent analysis of post-marketing safety information (Coloma, Trifirò et al. 2013). In the 
United States, the FDA Adverse Event Reporting System (FAERS) is the primary surveillance 
database used for the identification of safety problems of marketed drugs. Since its inception on 
1969, a list of drugs has been removed from the market or restricted to special requirements for 
prescription due to safety problems, representing 1% of marketed drugs (Wysowski and Swartz 
2005). Currently, FAERS contains over 5 million spontaneous reports of suspected ADRs, and 
receives an average of 300,000 reports per year among which the majority - 66% - come from 
the US (Coloma, Trifirò et al. 2013).  
Most of case reports collected by the SRS centers are either required to be submitted by 
pharmaceutical companies, or are voluntarily reported by healthcare professionals and 
consumers.  Each report usually includes one or more adverse events that appear to be associated 
with the administration of a drug; in addition, concomitant medications, indications and limited 
demographic information are also reported. Although case reports submitted to the SRSs do not 
necessarily imply causal relationships, the scenario of multiple reports which are similar and 
which independently originate from different sources raises the degree of suspicion, and 
sometimes have been considered sufficient for regulatory decisions (Brewer and Colditz 1999). 
SRSs can be effective in revealing unusual or rare adverse events that occur with the initial use 
or short-term use of medications. For example, methods using an SRS rapidly identified that 
temafloxacin was the cause for the ADR hemolytic anemia in otherwise healthy individuals 
because hemolytic anemia was rare in the general population and occurred within 1 week of drug 
use (Blum, Graham et al. 1994). However, SRSs do not rapidly lead to ADR detection if the 
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adverse event is relatively common but not necessarily drug-related in the general population 
such as approximately 30-year gap between the detection of autoimmune like disorders 
attributable to breast implant and its initial use(Kessler, Natanblut et al. 1993, Sanchez-Guerrero, 
Colditz et al. 1995). The autoimmune like symptoms are relatively common in women without 
implants and the recognition of this ADR is subjective, leading to underreporting when 
physicians and patients lack the knowledge of connecting breast implant to autoimmune like 
symptoms. Additional limitations of SRS include biased reporting influenced by media coverage 
or the length of time on market (Eberth, Kline et al. 2014), incomplete, inaccurate and duplicate 
reporting. For example, a study showed that patients were less likely to attribute an ADR to the 
prescribed medication than an expert panel that reviewed the event forms (Mitchell, Henry et al. 
1988), sampling biases whereas all the reports are related to corresponding ADRs so that 
information on the number of patients who take a drug of interest but do not develop an ADR is 
unknown (Brewer and Colditz 1999, Bate and Evans 2009), and duplicate reporting whereas 
multiple reports referring to the same adverse events are collected from different sources such as 
consumers, drug manufacturers and investigators (Sakaeda, Tamon et al. 2013).  
2.2.2 Observational healthcare data 
Based on the forgoing discussion, it is apparent that one of greatest limitations in the SRSs to 
post-marketing safety surveillance is their passive property and therefore delaying ADR 
detection. The imperative to shift the paradigm toward a more proactive approach calls for the 
attention of regulators and researchers (Gagne, Glynn et al. 2012). A proactive approach is a 
procedure that actively and routinely screen the data collected during the routine clinical care in 
order to generate hypothesis about the association between certain medications and selected 
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ADRs.  With the advance in information technology and increasing adoption across the world, 
electronic health records incorporated with detailed clinical data has become potential resources 
for proactive ADR detection (Psaty and Burke 2006, Stratton, Baciu et al. 2007, Platt, Wilson et 
al. 2009).  
An EHR is a longitudinal electronic record of patient information generated by one or more 
encounters in routine clinical care. This record usually includes structured information such as 
laboratory test results, medication orders and diagnostic codes for billing, and unstructured 
information in narrative text such as patients’ signs and symptoms, disease status and severity, 
and medical history. The EHR is initially designed and implemented to trace accurate, up-to-
date, and complete information about patients at the point of care. Nowadays, clinical researchers 
are increasingly interested in the secondary use of clinical data, which are promising for 
comparative effectiveness research, outcomes research, epidemiology, public health research and 
drug surveillance (Hersh 2007, Safran, Bloomrosen et al. 2007).  The function of drug 
surveillance based on EHR was exemplified by an initial pilot project by Partners Healthcare -
Adverse Drug Events Spontaneous Triggered Event Reporting (ASTER), which allowed selected 
physicians to report suspected ADRs in an automated way. The system prompted an alert for 
reporting when the physician indicated in the EHR that a drug had been discontinued because of 
an adverse event (Linder, Haas et al. 2010). However, upon the evaluation, they found that most 
of the ADRs captured and reported to FDA are known events, for example, ADRs that are 
included in product labeling, for the suspect drugs (Brajovic, PiazzaǦHepp et al. 2012). In terms 
of discovering novel ADRs, a study used the UK primary care databases IMS disease Analyzer 
MediPlus to show how longitudinal data may facilitate early signal detection (Bate, Edwards et 
al. 2004). Several studies showed the earlier detection of cardiovascular events associated with 
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the use of cyclooxygenase-2 inhibitors (coxibs) within an EHR database (Curtis, Cheng et al. 
2008). Moreover, a research explicitly demonstrated that when data were restricted to time prior 
to a regulatory action, the potential signals were much stronger when using the EHR than using 
SRSs (Patadia, Schuemie et al. 2014). However, EHRs introduce other challenges. First, usually 
only researchers affiliated with a medical center can access clinical notes within the institution 
even when they are de-identified (Friedman, Rindflesch et al. 2013), and consequently 
jeopardize the procedure for accumulating data from multi-site medical centers in order to detect 
rare events or study newly-marketed medications. Second, the data collection procedure and data 
quality of EHR vary across different providers and hospitals. Third, medical records usually 
mention the patient’s medications, symptoms, diseases, and procedures individually without 
mentioning their relationships. Fourth, most of the information is buried in narrative clinical 
notes, and is inaccessible for automated applications.  
Similar to EHRs, linked administrative databases, such as Medicare and commercial healthcare 
claims databases, are emerging as a source for ADR detection. In comparison to EHRs, 
structured claims data, consisting of diagnosis codes, procedure codes and prescriptions, have 
relatively low sensitivity for detecting ADRs, weaker coverage of symptomatology, and are 
vulnerable to inaccuracies as they are oriented toward billing(Nadkarni 2010, Classen, Resar et 
al. 2011).  
2.2.3 Prescription event monitoring databases 
Prescription-event monitoring (PEM) was first suggested 25 years ago as a way to monitor the 
overall safety of newly marketed medicines as used in real-life clinical practice, usually in 
cohorts of at least 10,000 patients. The number of 10,000 patients was chosen since it is 
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estimated that a sample size of 10,000 patients should detect at least three ADRs with 85% 
power even when ADR occurs at a rate of 1 in 2000 and assuming the background rate is zero 
(Strom 2011). The United Kingdom was the first country to adopt PEM which actively solicit 
information of suspected ADRs involving demography, indication, dose, reason for stopping 
medication (if applicable), any events that had occurred since starting medication, whether any 
events were suspected to be ADRs and whether events were reported to the UK Regulatory 
Authority or manufacturer (Rawson, Pearce et al. 1990) (Bate and Evans 2009). A similar system 
called Intensive Medicines Monitoring Programme is carried out in New Zealand which 
monitors the first 10,000 patients exposed to a new drug for a mean of almost five years (Coulter 
2000).  
In general, prescription follow-up information provides a denominator - the number of patient 
exposed and a numerator - the number of ADRs - for calculating ADR rates. Reporting rates are 
hence much higher than voluntary reporting. An example of ADRs identified by PEM include 
cough with captopril (Coulter and Edwards 1987). However, since PEM only contains details of 
clusters of patients exposed to a particular drug, the lack of an adequate control group is a 
limitation. For example, tolterodine did not show evidence of hallucinations as an ADR because 
the control group contained patients prescribed other drugs known to cause hallucinations. When 
the data from these patients were removed, an ADE signal for tolterodine was discovered 
(Heeley, Wilton et al. 2002).  
2.2.4 Other promising data sources for pharmacovigilance 
Systematic review of biomedical literature is a comprehensive scientific evidence source to 
confirm or reject a possible drug-ADR causal relationship. Shetty et al expedited this process by 
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retrieving possible ADR case reports from MEDLINE on the basis of National Library of 
Medicine’s (NLM) Medical Subject Headings (MeSH) index and a Lasso-based document 
relevance classifier, and then applied a disproportionality analysis to identify statistically 
significant drug-ADR associations(Shetty and Dalal 2011). Avillach et al. devised an ADR 
identification process based entirely on MeSH annotations. The MeSH subheadings of 
‘chemically induced’, ‘adverse effects’ and ‘pharmacological action’ were used to link drugs and 
medical conditions in an article as candidate drug-ADR pairs. They then identified a possible 
drug-ADR association by using a threshold of three articles whose MeSH annotations contained 
the studied drug-ADR pair (Avillach, Dufour et al. 2013). In contrast, Wang et al developed a 
machine learning approach based on the text of the article from PubMed to support 
pharmacovigilance for particular ADRs they were interested in (Wang, Haerian et al. 2011). 
User-posted data on social media has become a useful resource for ADR monitoring. In terms of 
sources, both health-related sites, such as PatientsLikeMe and DailyStrength, and general social 
media data, such as Twitter, have been used for ADR detection. In a recent paper, Freifeld et al. 
described an analysis of Twitter posts for references to drugs and adverse events, with 
comparison to reporting patterns in the US FDA FAERS and showed that the Spearman rank 
correlation rho of 0.75 (p < 0.0001) between Proto-AEs reported in Twitter and FAERS by SOC 
(Freifeld, Brownstein et al. 2014). Health-related sources tend to contain higher proportions of 
relevant data while the amount of data from general social media websites is significantly larger. 
In terms of methods for detecting ADRs, Medawar et al. initiated a study in 2001, which 
validated a relationship between suicidal thoughts and the antidepressant paroxetine by 
reviewing posts to an online discussion board and emails sent to a major British Broadcasting 
Corporation (BBC)-TV documentary programme (Medawar, Herxheimer et al. 2002). Lately, 
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supervised classification techniques for detecting posts associated with ADR mentions, and 
lexicon-based approaches for extracting ADR mentions from texts have become popular (Sarker, 
Ginn et al. 2015). In parallel, the Internet search patterns have been explored for similar 
purposes. For example, White et al. conducted two studies to examine the feasibility of a signal 
detection system based on the web search logs (White, Tatonetti et al. 2013, White, Harpaz et al. 
2014).  
2.3 Methods applied in pharmacovigilance 
2.3.1 Disproportionality analysis 
Disproportionality analyses (DPA) are routinely applied to SRSs (A. Bate et al., 1998; W. 
DuMouchel & Pregibon, 2001; W DuMouchel, 1999; Lindquist et al., 1999; Lindquist, Stahl, 
Bate, Edwards, & Meyboom, 2000; Noren, Bate, Orre, & Edwards, 2006) to measure the 
strength of reported drug-event associations. DPA involves calculating surrogate observed-to-
expected ratios in which each drug-ADR pair is compared to background across all other drugs 
and events in the database. Two of the most widely cited measurements are the relative reporting 
ratio (RRR) and reporting odds ratio (ROR). RRR is the ratio between the number of reports 
concerning a particular drug-ADR combination to an expected number under the assumption that 
the drug and ADR occur independently (Norén, Hopstadius et al. 2013). ROR considers SRS as 
source data for a case-control study, under the assumption that the odds of the ADR are not 
affected by the drug (Rothman, Lanes et al. 2004). Both RRR and ROR do not address the 
sampling variance issue. Multi-item Gamma Poisson Shrinker (MGPS) and Bayesian confidence 
propagation neural network (BCPNN, information component (IC) is the statistical score) adopt 
Bayesian approaches to cope with sampling variance by shrinking RRR or IC towards a prior 
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when less data concerning the drug-ADR pair is available (DuMouchel 1999). MGPS method is 
the routine ADR detection algorithm used in the FDA FAERS, and BCPNN used to be the 
routine ADR detection method applied in the WHO VigiBase, which was replaced by a much 
simpler method developed by Noren et al recently (Norén, Hopstadius et al. 2013). Lately, the 
DPA method was adapted to take temporal information into account to measure the drug-ADR 
associations in observational healthcare databases, such as healthcare claims database and 
structured electronic health records (Schuemie 2011, Zorych, Madigan et al. 2013). Meanwhile, 
the DPA method was applied to measure the drug-ADR association on the basis of ADR case 
reports in the MEDLINE database (Shetty and Dalal 2011).   
However, all the above methods measure lower order associations, such as a single drug-ADR 
pair without considering the effect of confounding factors. A confounder is an extraneous 
variable, either observed or unobserved, that mediates an association between two other 
variables. For example, alcoholism is a confounder that could lead to a suspicious relationship 
between the medication Naltrexone and pancreatitis because Naltrexone treats alcoholism, which 
often leads to pancreatitis. If not properly accounted for, confounding may lead to the discovery 
of suspicious associations and therefore erroneous study conclusions.  
2.3.2 Multiple regressions 
Randomization is an experimental design to randomly allocate subjects to the treatment group 
and other control groups so that the groups have similar distributions of age, gender, behaviors, 
and virtually all known and unknown possible confounding factors. The data collected by the 
randomization design are supposed to be free of confounding effect. However, as in the case of 
SRS and observational healthcare databases where data have already been collected, the 
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characteristics of patients in exposure or unexposed group could not be balanced through 
randomization, confounding should be addressed in the analysis stage. Stratification is a standard 
procedure to alleviate confounding effects but it is not effective in situations where a large 
amount of potential confounders need to be examined. A more appropriate approach to handling 
confounding is by the use of multiple logistic regression, or new extensions of logistic regression 
to very-large-dimensional data, known as regularized or Bayesian logistic regression (BLR). 
Caster et al. described an application of BLR to the WHO SRS, involving an attempt to address 
confounding caused by co-medication and a “masking” effect (Caster, Norén et al. 2010). 
Masking effect is the suppression of a statistical reporting association between a drug and an 
adverse event due to large numbers of reports for that adverse event in connection with another 
drug or drugs (Wang, Hochberg et al. 2010). For example, the association between the anti-
depressive drug venlafaxine and the ADR rhabdomyolysis were masked by media focus on the 
withdrawal of a drug (cerivastatin) causing rhabdomyolysis (Caster, Norén et al. 2010). Later on, 
regularized logistic regression is applied to the healthcare claims databases and EHRs to 
eliminate confounders (Harpaz, Haerian et al. 2010, Ryan, Madigan et al. 2012, Li, Salmasian et 
al. 2013). Propensity score (PS) method is another commonly used regression-based analytic 
approach for controlling confounding in the analysis stage (Rosenbaum and Rubin 1983, Patrick, 
Schneeweiss et al. 2011). Propensity scores combine information from a large number of 
covariates into a single variable representing a subject’s probability of receiving a particular 
treatment, given the measured characteristics. This score can be used for matching, stratification, 
as a weighting factor, or as an adjustment factor in multivariable regression (Stürmer, Joshi et al. 
2006). Tatonetti et al used PS method to identify potential drug-drug interaction between 
paroxetine and pravastatin that could possibly cause hyperglycemia (Tatonetti, Ye et al. 2012).  
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2.3.3 Epidemiology design 
Epidemiological methods, including cohort, case-control and self-controlled designs, have been 
frequently applied to observational healthcare data. Cohort design identifies two subgroups of 
the population on the basis of the presence or absence of the exposure (Rothman, Greenland et 
al. 2008). The non-exposure group could consist of patients who did not take particular 
medications or who took other medications whose indication is the same to the studied 
medication. The association is measured by comparing the presence and the absence of the 
outcome between two groups. A case-control study has the same specifications as a cohort study, 
except that the roles of exposure and diseases are reversed (Rothman, Greenland et al. 2008). 
The case group consists of patients developing the disease and the control groups consist of 
patients who are free of the disease. The relationship is measured by the presence and absence of 
exposure for individuals in both groups. The main advantage of case–control studies as 
compared with alternative study designs such as cohort designs is their data efficiency, which 
permits the study of rare events (Jewell 2003). Self-controlled design can produce results that are 
statistically and clinically valid with far fewer patients than would otherwise be required by 
using each patient as his or her own control. The self-controlled case series (SCCS) is a type of 
self- controlled design which assumes that ADRs arise according to a nonhomogeneous Poisson 
process, with each subject having an individual baseline of non-exposure event rate that is 
constant over time, and with periods of exposure resulting in a multiplicative effect on the 
baseline rate (Simpson 2011). The above three designs were intensively examined by OMOP on 
the basis of five databases. In an experiment conducted by OMOP, high dimensional propensity 
score based cohort study achieved a sensitivity of 56%, specificity of 82%, and positive 
predictive value of 38% in the detection of 53 associations corresponding to true ADEs and 
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negative controls. The implementation of a case–control design achieved close to 100% 
sensitivity, but at the expense of extremely low specificity of 15% (Ryan, Madigan et al. 2012). 
Self- controlled methods, such as self-controlled case series, temporal pattern discovery and self-
controlled cohort, had higher predictive accuracy than cohort and case–control methods across 
all databases and outcomes. However, the distributions of point estimates across all analysis 
methods for the negative controls, which are supposed to be centered on zero, were positively 
biased. (Ryan, Stang et al. 2013).  
2.3.4 Unsupervised machine-learning methods  
Unsupervised machine-learning approaches, such as clustering, association rule mining and 
network analysis, have been used for the identification of more complex or higher-dimensional 
drug safety phenomena as well as for data abstraction and pattern discovery. In general, the 
clustering algorithms could be used to group patients with similar symptoms or diagnoses, which 
segment a large patient population to a smaller set of specific homogeneous subgroups (clusters) 
without losing much information about the whole population.  The drug-ADR associations could 
further be calculated within these relatively homogeneous clusters and summarized using 
techniques such as Cochran-Mantel-Haenszel method. Because of the heterogeneity between 
clusters, this analysis can also be helpful in hypothesis development about the nature of the 
variation between subgroups. For example, if a database contained details of different cardiac 
pathologies (e.g. valvular heart disease) and medication (e.g. fenfluramine-phentermine), 
clustering analysis may have segregated patients according to heart disease and identified 
fenfluramine-phentermine as one of the main factors in this group. We could then explore the 
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hypothesis of an association or causal link between cardiac valvular disease and fenfluramine-
phentermine (Wilson, Thabane et al. 2004). 
2.4 Integration of ADR evidence from heterogeneous databases 
Regulatory decision-making based on integrating available research data from multiple data 
sources to determine whether a drug is safe is a complex process (Anello and O'neill 1996). The 
main use case for leveraging multiple data modalities is to improve signal detection via evidence 
combination. In this regard, the questions that need to be studied are whether we should use 
some data sources for hypothesis generation while reserving others for confirmation, or combine 
data sources in a novel way to generate hypothesis.  
Tatonetti et al. discovered a potentially new drug-drug interaction, which can lead to unexpected 
increases in blood glucose levels, between paroxetine and pravastatin based on SRS, and then 
validated this interaction using multi-center EHRs (Tatonetti, Denny et al. 2011, Tatonetti, 
Fernald et al. 2012). Duke et al. predicted probable novel myopathy-associated drug-drug 
interactions based on the literature, and evaluated them using a large EHR database(Duke, Han et 
al. 2012). Xu et al boosted drug-ADR pairs’ signals generated from FAERS by incorporating the 
information about their MEDLINE occurrences. The key assumption in their study was that if a 
drug-ADR pair appears in both MEDLINE and FAERS database, then this pair likely has a true 
ADR relationship and if this pair also appears in FAERS many times, then the probability of it 
being a true “drug CAUSE ADR” pair is high (Xu and Wang 2014). Harpaz et al. claimed that a 
combinatorial investigation of SRS and the EHRs either lead to increased evidence or statistical 
power of findings, or would facilitate new discoveries that may not be possible with either source 
separately (Harpaz, Vilar et al. 2012). In particular, the study analyzed 4 million reports obtained 
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from FAERS together with information extracted from 1.2 million EHR narratives using 
disproportionality analysis to generate a list of ADRs and then re-ranked them on the basis of 
signal strength calculated from the EHR. The results showed that the accuracy of signal 
detection, measured by the ‘Precision at K’ metric (Baeza-Yates and Ribeiro-Neto 1999, Liu and 
Zsu 2009), was improved. A reference standard of three serious adverse reactions and over 600 
established and plausible ADRs was used to evaluate the proposed approach against the single 
FAERS-based signal detection system. Established ADRs are drugs confirmed to be causally 
related to the ADR and plausible ADRs are drugs that have a high likelihood of being causative. 
The combined signaling system demonstrated a statistically significant large improvement over 
the FAERS in the precision of top-ranked signals (i.e. from 31 % to almost threefold for different 
evaluation categories). The study concluded with promising initial evidence that exploring 
FAERS and EHR data in the scope of replicated signaling can improve the accuracy of signal 
detection in specific cases. Vilar et al conducted two studies of re-ranking the ADR signals 
mined from observational health databases. One was based on a single EHR system and the other 
was based on a large-scale claims database using 2D structure similarity for enrichment analysis 
(Vilar, Harpaz et al. 2011, Vilar, Ryan et al. 2014). However, the above studies used a single 
data resource to generate ADR signals and then independently used another resource for 
validation or enrichment analysis. Harpaz et al. proposed a Bayes model to computationally 
combine ADR signals from a disparate SRS of about 5 million adverse event reports collected by 
the FDA and from healthcare data corresponding to about 46 million patients from a healthcare 
claims database, and the performance was measured based on a reference standard of 4 ADRs 
and 399 test cases provided by OMOP (Harpaz, DuMouchel et al. 2013). The metrics used were 
the area under receiver operation characteristic curve (AUC) and partial AUC.  Results 
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demonstrated that the proposed method led to a statistically significant and substantial 
improvement in signal detection accuracy, averaging 40% over the use of each source 
independently, and an area under the ROC curve of 0.87. Another advantage of this method is 
that the method does not require labeled (training) samples whose availability is currently 
limited. The study of Liu et al. also followed an integrative perspective for ADR detection by 
utilizing chemical - e.g. compound fingerprints or substructures, biological – e.g. protein targets 
and pathways, and phenotypic properties of drugs – e.g. indications and other known ADRs (Liu, 
Wu et al. 2012). This integrative analysis was evaluated based on the prediction of 1,385 known 
ADRs of 832 approved drugs, through five different analysis methods, namely logistic 
regression, naive Bayes, K-nearest neighbor, random forest and support vector machine. The 
detailed data were obtained from public databases, while the evaluation was based on accuracy, 
precision, and recall, which were determined by the best operating points of the global ROC 
curve on the basis of the prediction scores for all ADRs. The study indicated that from the three 
types of information, phenotypic data were the most informative for ADR prediction. However, 
when biological and phenotypic features were added to the baseline chemical information, the 
proposed prediction model achieved significant improvements and successfully predicted ADRs 
associated with the withdrawal of specific drugs. 
Patadia et al evaluated performance of electronic healthcare records and spontaneous reporting 
data in drug safety signal detection on the basis of ten events with known positive and negative 
reference sets. Signals were identified when respective statistics exceeded defined thresholds. 
The results showed that when using all cumulative data, signal detection in SRS data achieved 
higher specificity and sensitivity than EHR data. However, when data were restricted to time 
prior to a regulatory action, the appropriate use of healthcare data had an potential for earlier 
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detection of drug safety signals before healthcare professionals report them to an SRS system 
(Patadia, Schuemie et al. 2014). 
It is believed that one of the next breakthroughs in pharmacovigilance depends on a 
comprehensive approach that examines ADR-related information from a diverse set of 
potentially complementing data sources such as SRS, electronic healthcare data, biomedical 
literature, chemical information and phenotypic information, to detect and validate novel ADRs.  
 
2.5 Reference standards used in Pharmacovigilance 
A central challenge in ADR detection is the need for publically available and sufficiently large 
reference standards to properly evaluate the performance characteristics of the data mining 
algorithms when applied to various data sources. There have been previous attempts to develop 
reference standards, however, the procedure to generate them was not transparent and 
systematic, or lacked negative controls. For example, Lindquist et al. evaluated the performance 
of the BCPNN based on the Martingdale and Physician Desk Reference compendium of drug 
information(Lindquist, Ståhl et al. 2000). Hochberg et al. selected 27 drugs and classified 
adverse events based on level of evidence from product labeling and literature review, and used 
this reference event database to evaluate three algorithms (Hochberg, Hauben et al. 2009). 
Pharmacovigilance research has become an important topic in the biomedical informatics field. 
Wang et al. conducted a feasibility study of using NLP, Statistics, and EHRs for the 
pharmacovigilance and selected seven drugs/drug classes with their 132 known ADRs to 
evaluate the system (Wang, Hripcsak et al. 2009). Harpaz et al and Li et al evaluated their 
regression-based ADR detection systems on the basis of three ADRs – rhabdomyolysis, 
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pancreatitis and QT prolongation (Harpaz, Haerian et al. 2010, Li, Salmasian et al. 2013). The 
reference standard for the known drugs causing these three ADRs was created using evidence 
from literature, Micromedex and drug labels, and was classified into two categories – established 
and plausible (Harpaz, Vilar et al. 2012). LePendu et al evaluated their system using the 
manually curated reference standard of 28 positive associations and 165 negative associations 
spanning 78 drugs and 12 different events for single drug–adverse event associations (LePendu, 
Iyer et al. 2013). Quite a few studies evaluated their systems using the popular database - Side 
Effect Resource (SIDER), which is a publicly available knowledge base that contains a total of 
99,423 drug-ADR pairs regarding 4192 ADRs and 996 drugs (Leaman, Wojtulewicz et al. 2010, 
Nikfarjam and Gonzalez 2011, Shang, Xu et al. 2014). The information in SIDER is 
automatically extracted from public documents and package inserts but SIDER does not 
differentiate carefully the degree of certainty for a drug ADR signal when it is appearing in 
different sections of the drug label, and therefore some drug ADR pairs could be false positive 
signals. Other evaluations were performed via comparative analysis with findings from previous 
studies, for example, Caster et al compared the ADR signals generated by Lasso Logistic 
Regression (LLR) with the ones produced by the routine method information component (IC) 
used in the Vigibase and found that LLR was able to detect some established drug safety issues 
earlier than the IC (Caster 2007). Xu et al compared ADR signals detected by mining literature 
with the ones mined from FAERS (Xu and Wang 2014). 
Recent efforts made by the EU-ADR projects and OMOP have made substantial progress in 
developing reference standards. The EU-ADR projects constructed a reference standard for ten 
top-ranked events judged as important in pharmacovigilance. A stepwise approach was 
employed to classify drug-ADR pairs to positive or negative test cases based on MEDLINE-
24 
indexed publications, drug product labels, spontaneous reports made to the WHO’s 
pharmacovigilance database, and expert opinion, resulting in 44 positive and 50 negative test 
cases, with up to 5 positive and negative controls for 10 ADRs (Coloma, Avillach et al. 2013). In 
its initial experiments, OMOP constructed a reference standard of 53 drug-ADR pairs which 
were classified as 9 positive test cases and 44 negative test cases on the basis of product labeling 
and expert consensus (Ryan, Madigan et al. 2012, Ryan, Schuemie et al. 2013). Later on, they 
selected four ADRs and classified drugs associated with these ADRs on the basis of evidence 
from product labeling, systematic review of the literature and a textbook about drug-induced 
diseases resulting in 399 test cases – 165 are positive cases and 234 are negative controls(Ryan, 
Schuemie et al. 2013).  
The resulting reference standards are by no means definitive, however, and should be seen as 
dynamic. As knowledge on drug safety evolves over time and new issues in drug safety arise, 
these reference standards should be re-evaluated and expanded. Therefore, the temporal 
information is essential about when a true positive drug-ADR signal becomes known or up to 
when there is no supporting evidence about a drug causing an ADR. Harpaz designed a time-
index reference standard, which was systematically curated from drug labeling revisions, such as 
new warnings, which were issued and communicated by the US Food and Drug Administration 
in 2013. The reference standard includes 62 positive test cases and 75 negative controls, and 
covers 44 drugs and 38 events(Harpaz, Odgers et al. 2014). However, the date of revising 
labeling, are unlikely to truly represent the time of first detection of a new safety signal. For 
example, Niu et al claimed that the use of data mining with the Vaccine Adverse Event 
Reporting System (VAERS), the US surveillance system for monitoring vaccine safety, had 
detected a signal for intussusception earlier than approved drug label (Niu, Erwin et al. 2001). In 
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fact, the first indication of a potential signal actually occurred prior to approval and was 
described in the original package insert before it became publicly available.  The common 
evaluation metrics of evaluation are recall, precision, F-score, AUC and partial AUC.   
2.6 Related Work 
2.6.1 Natural language processing 
The key challenge in using clinical information for pharmacovigilance is that they are 
represented in free-text. With the emergence of high throughput technologies, natural language 
processing (NLP) has been applied in biomedicine. A typical procedure to process the free-text 
clinical notes comprised several NLP subtasks, including named entity recognition, negation 
detection and relation extraction. A brief description of these tasks is provided by Friedman and 
Elhadad (Friedman and Elhadad 2014)and Nadkarni (Nadkarni, Ohno-Machado et al. 2011) et al. 
The commonly used systems in biomedical domain include MetaMap, MedLEE, BioMedLEE 
and MGrep (Aronson 2001, Chen and Friedman 2004, Friedman, Shagina et al. 2004, Jonquet, 
Shah et al. 2009). Medical Language Extraction and Encoding (MedLEE) is a natural language 
processing system that has been used to extract and encode information in clinical narratives for 
a large number of different applications and studies.  For a given report, MedLEE produces a set 
of findings, such as problem, procedure, device, and medication, along with associated 
modifiers, such as certainty, degree, status, body location, and section.  
NLP was initially proposed to be applied for the active computerized pharmacovigilance by 
Wang et al (Wang, Hripcsak et al. 2009). They demonstrated that the framework based on NLP, 
EHR and statistics could potentially unveil drug safety profiles throughout their entire market 
life. Haerian  et al applied the NLP and a knowledgebase to exclude cases in which the patient’s 
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disease was responsible for the event rather than a drug, which is crucial for mining EHR for the 
detection of ADR (Haerian, Varn et al. 2012). LePendu et al developed a high-throughput NLP 
tool to transform clinical notes into a feature matrix encoded using medical terminologies, and 
then used statistical method to detect ADRs (LePendu, Iyer et al. 2013).  
2.6.2 Biomedical ontologies 
The Unified Medical Language System (UMLS) is one of the major resources, which comprise 
three components: the Metathesaurus, the Semantic Network, and the SPECIALIST Lexicon. 
The UMLS Metathesaurus is a compendium of over 150 controlled vocabularies or ontologies 
containing 3 million biomedical concepts that are associated with synonyms, semantic groups 
and relationships between two concepts (Bodenreider 2004). In addition, the UMLS uses the 
concept unique identifier (CUI) to link terms with the same meaning together. Among all the 
contributing sources are two vocabularies utilized commonly in the NLP task for this 
dissertation. RxNorm (Liu, Ma et al. 2005) is an initiative for creating standard names for 
clinical drugs, and defining several types of relationships between concepts that are related to 
generic classes and trade names of drugs, such as tradename_of and has_tradename,  which are 
used to map all trade name to  their generic names (http://www.nlm.nih.gov/research/umls/ , Liu 
S 2005, Chen, Hripcsak et al. 2008). The UMLS Semantic Network provides a semantic 
categorization of the UMLS concepts and includes a set of 135 semantic types such as Disease 
or symptom (T047) and Pharmacologic Substance (T121), as well as semantic relations defining 
relations between these types.  
Search tool for interactions of chemicals (STITCH) integrates information about interactions 
from metabolic pathways, crystal structures, binding experiments and drug–target relationships. 
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STITCH maintains synonym lists for chemicals, and relationships between drugs and their 
chemical compounds. (Kuhn, von Mering et al. 2008) For example, quinapril hydrochloride and 
Hemokvin are mapped to the main ingredient quinapril. STITCH was used to link drug brand 
names to their chemical compound names.  
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CHAPTER 3 A method for controlling complex confounding effects in the detection of 
adverse drug reactions using electronic health records 
 
3.1 Introduction 
EHRs contain comprehensive patient information collected during routine practice (Cox, Martin 
et al. 2009). Unlike spontaneous reporting systems, they are not subjective regarding ADRs. 
However, EHRs introduce other challenges. First, most of the information is buried in narrative 
clinical notes, and is inaccessible for automated applications. This can be addressed by using 
natural language processing (NLP) systems, which encode narrative clinical notes (Meystre, 
Savova et al. 2008, Savova, Masanz et al. 2010, Xu, Stenner et al. 2010).  Second, the vast 
amount of clinical narrative information in the EHR exacerbates the problem of confounding by 
introducing many conditions. Third, records usually mention the patient’s medications, 
symptoms, diseases, and procedures individually without mentioning their relationships. 
Therefore, statistical methods are needed to obtain associations, which do not denote 
relationships. For example, a statistical association between a medication and a condition may be 
a treatment, an ADR, or an indirect association stemming from another event, for example, a 
confounder (Cao, Hripcsak et al. 2007, Wang, Hripcsak et al. 2009).  Since ADRs occur rarely, 
most associations are due to confounding. For instance, when certain serious ADRs were 
identified using abnormal laboratory signals (ALS), 70% were not drug-related, but 
corresponded to spurious associations between drugs and the adverse events (Ramirez, Carcas et 
al. 2009). ADR signals detected in the EHR are likely to be confounded by co-medication, by 
29 
indication, by comorbidity, or any combination of the three. Confounding by co-medication 
occurs when two or more medications are frequently prescribed together, but only one causes the 
ADR of interest. For example, Rosinex causes nausea, but because Rosinex and Ganclex are 
frequently prescribed together, a spurious association between Ganclex and nausea may also 
occur (Hauben, Madigan et al. 2005). Confounding by indication occurs when medications are 
prescribed to treat symptoms or manifestations of an ADR before the ADR is diagnosed. For 
example, the medication fentanyl may be prescribed for patients who have severe pain before the 
diagnosis of the condition responsible for the pain. Confounding by comorbidity occurs when an 
ADR is associated with the disease which the medication is used to treat.  For example, 
Naltrexone may be associated with pancreatitis because it treats alcoholism, which often leads to 
pancreatitis. In this study, we focus on eliminating confounding by co-morbidity.  
To ascertain a causal relationship between a drug and an ADR, confounders need to be identified 
and removed from the observed marginal associations.  A marginal association is a relationship 
between two variables in the marginal table, and can be used to test for marginal independence 
between two variables while ignoring the third. Removing confounding effect is critical for 
observational studies, where the data are collected without randomization or strict 
inclusion/exclusion criteria (Greenland and Morgenstern 2001, Brookhart, Stürmer et al. 2010). 
A study conducted by Harpaz et al selected potential confounders which were highly associated 
with the outcome ADR and then determined whether an association between a medication and an 
ADR existed based on changes in association strengths with and without the 
confounders.(Harpaz, Haerian et al. 2010) These identified confounders are actually more similar 
to risk factors (RFs) for an ADR (hereafter Harpaz’s method is referred to as RF). The 
propensity score method (PSM) also controls for confounding, and has been applied to health 
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claims databases for drug effectiveness comparative studies (Schneeweiss and Avorn 2005, 
Schneeweiss, Rassen et al. 2009, Brookhart, Stürmer et al. 2010) and ADR detection. (Caster 
2007, Caster, Norén et al. 2010, Tatonetti, Ye et al. 2012) The PSM estimates each patient’s 
probability of the exposure of medication, which it uses as a surrogate to mitigate confounding. 
The RF method identifies the confounders only by their associations with the ADR, while the 
PSM selects confounders based only on their associations with the medication. In addition to 
that, PSM selects potential confounders on an individual basis that are often correlated with each 
other. However, some conditions no longer confound the drug-AE association in the presence of 
other conditions. Including these unnecessary conditions in the analysis leads to increased 
uncertainty and decreased statistic power.  The algorithm we propose takes both types of 
associations into account, which helps avoid detecting inappropriate confounders. We apply our 
method to two serious ADRs, rhabdomyolysis and pancreatitis, to study performance, but it is 
generalizable and can be used to detect other ADRs.  
3.2 Method 
3.2.1 Study setting 
The study was conducted at Columbia University Medical Center/New York Presbyterian 
Hospital (CUMC/NYPH), after Institutional Review Board approval. EHR data consisted of 
retrospective narrative outpatient visits, admission notes, discharge summaries, and structured 
medication orders and laboratory results from 2004 to 2010. Narrative reports and structured 
medication orders were used to obtain the patients’ medical conditions and medications, and 
laboratory data was used to detect ADR occurrences.  
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3.2.2 Methodological Framework 
Figure 3.1 is an overview of the methodology, which consists of 5 steps:  1) collecting the 
appropriate EHRs and performing NLP of the narrative notes to obtain structured coded data; 2) 
creating each ADR case group, generating the 2×2 contingency tables, and identifying initial 
candidate drug safety signals; 3) identifying potential confounders; 4) estimating medication-
ADR associations while adjusting for confounders; and 5) determining medication-ADR signals.   
 
Figure 3.1 Methodological Framework 
 
 
3.2.2.1 Data collection and preparation  
An NLP system, MedLEE, was used to structure and encode the narrative notes. (Friedman, 
Shagina et al. 2004) MedLEE identified medical concepts, such as medications, diseases and 
symptoms, and mapped the concepts to the Unified Medical Language System (UMLS) concept 
unique identifiers (CUIs) to standardize them. (Bodenreider 2004). MedLEE also identified 
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modifiers of the medical concepts, such as time and negation. By using them, events that were 
not experienced by the patient or that occurred in the past were excluded.(Chapman, Bridewell et 
al. 2001) For example, chest pain in the sentence “The patient had 3 admissions in the past for 
chest pain”, was excluded as a current problem. Medication names were normalized to their 
generic names. As mentioned in Chapter 2, the UMLS Metathesaurus includes relationships 
among concepts drawn from its various source terminologies, and the hierarchic relations 
provide a basis for normalizing drug brand names to generics and linking specific drugs to drug 
classes. We retrieved all the “isa,” “inverse_isa,” “has_tradename,” and “tradename_of” relations 
of each extracted drug concept to create the hierarchy, and also used “has_ingredient” and 
“has_active_ingredient” relations to help determine whether a concept is a drug or a drug class. 
For example, the trade name Lipitor (UMLS id entifier C0593906) was normalized to the generic 
atorvastatin (UMLS identifier C0286651). Finally, we captured temporal information 
corresponding to dates of the laboratory tests, dates of admission and discharge for inpatients, 
and dates of office visit for outpatients. 
3.2.2.2 Identify candidate drug safety signals 
The two ADR groups were identified based on abnormal laboratory tests. Rhabdomyolysis was 
based on a serum CK >= 1000 U/L, (and pancreatitis was based on an amylase >= 300 U/L or 
lipase >= 120 U/L.  The control groups for each ADR consisted of patients in the same 
population without the particular ADR. We analyzed associations of ADRs by considering 
medications that were mentioned before the ADR occurred as the exposure should always 
precede the ADR. We utilized two criteria to select medications in the case group: 1) 
medications mentioned in a clinical note were included if the note was written before the initial 
date of the abnormal lab signal (ALS), or 2) only medications  mentioned in the sections 
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Medications on Admission or Current Medications were included if the note was written during 
the same admission or office visit corresponding to the date of the first ALS because these 
sections generally specify medications taken prior to the ADR. In contrast, all the medications 
for the control patients were collected. Subsequently, we constructed 2×2 contingency tables for 
each medication-ADR pair, as shown in Table 3.1.   
Table 3.1 Two by two contingency table 
 ADR     
(Present of outcome) 
 No ADR 




a  b  (a+b) 
No medication   
(No exposure)  
c  d  (c+d)  
 (a+c)  (b+d)  (all patients)  
 
Using formula 3.1 we calculated the Odds Ratio (OR) for each contingency table to obtain an 
initial set of drugs associated with the ADR. An OR >1 indicates that the chance for developing 
an ADR is higher for those who took the medication than who did not. We used the Fisher’s 
exact test(Upton 1992) to test whether the ORs were significantly larger than 1, and ranked the 
resulting p-values from smallest to largest. We selected the top K drugs using a family-wise 
False Discovery Rate (FDR) (Benjamini and Hochberg 1995)  controlled at 5%.  
Equation 3.1 Odds Ratio 
ܱܴ஺஽ோǡோ௫ ൌ
ܴܦܣሺݏܱ݀݀ ൌ ͳȁܴݔ ൌ ͳሻ
ܴܦܣሺݏܱ݀݀ ൌ ͳȁܴݔ ൌ Ͳሻ ሺܺሻݏܱ݀݀݁ݎ݄݁ݓ ൌ
ሻݔሺݎܲ
ͳ െ  ሻݔሺݎܲ
Rx represents the drug of interest 
3.2.2.3 Identify confounders for specific medications  
Potential confounders included diseases and symptoms of individual patients. We calculated the 
OR of each condition with the drug (ș1), and with the ADR (ș2), and identified a condition as a 
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confounder for the drug-ADR association if: (1) both ș1 >1 and ș2 >1, and (2) ln(ș1×ș2) > 0.2.  
The rationale is that a confounder could falsely amplify the ADR signal if and only if it is 
positively associated with both the drug and the ADR, and the associations are strong. For 
example, as shown in Figure 3.2, alcoholism was positively associated with both Naltrexone (ș1 
= 58.8), and pancreatitis (ș2 = 4.09), and the associations were strong (ln(ș1×ș2) = 5.74). 
Therefore, alcoholism was considered a potential confounder for Naltrexone-pancreatitis. 
Figure 3.2 Example of confounding by comorbidity 
 
 
3.2.2.4 Estimate the medication-ADR associations adjusting for potential confounders  
We fit the logistic regression model shown in formula 3.2 to re-evaluate the drug-ADR 
association while adjusting for the identified confounders simultaneously.   
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Equation 3.2 Logistical regression model 




                                            Rx represents the medication of interest 
                                            ȕ is the effect of the medication associated with the ADR after adjusting for all the Cis 
 concerning the ADR ܥ ௜is the effect of the i-th confounderߛ                                           
 
In last step, the potential confounders Ci were identified on an individual basis, and were often 
correlated with each other. Hence some conditions no longer confounded the drug-AE 
association in the presence of other conditions. Including irrelevant items could inflate the 
estimation variability and undermine the statistical power for detecting ADR associations.  To 
address such over-controlling, we incorporated a Least Absolute Shrinkage and Selection 
Operator (LASSO) type regularization into the estimation of the model which automatically 
selected the significant Ci’s (Tibshirani 1996, Zou and Hastie 2005). The LASSO involves a 
turning parameter O , which controls the penalty on the model complexity. We selected an 
optimal O  by ten-fold cross-validation. 
To relieve the computational burden, we included the conditions into formula 3.2 in groups 
instead of all at once. Specifically, we ranked the Ci’s by the strength of their association with 
the ADR (ș2). Instead of including all the Ci’s at once, we only included the top 500 
confounders, and then used LASSO to eliminate the insignificant conditions. We repeated this 
procedure by iteratively adding the next 500 confounders. The method stopped and the drug-
ADR association was rejected if after adding confounders, there was no association between 
medication and ADR. However, if after adding all confounders, the association still existed, this 
was considered a possible ADR signal. 
3.2.2.5 Determine the adjusted medication-ADR signals    
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For each drug-ADR association, we tested the null hypothesis  ȕ =0 using the Wald test 
(Gourieroux, Holly et al. 1982).  If ȕ =0 was accepted,  it implied that the observed marginal 
drug-ADR association was due to the existing confounding conditions; otherwise, the medication 
was considered to be associated with the ADR even after adjusting for the confounders. 
3.2.3 Evaluation Design 
3.2.3.1 Reference standard 
The reference standard consisted of drugs implicated in causing rhabdomyolysis and pancreatitis. 
It was constructed independently by a pharmacological expert using Micromedex, literature 
reviews and published reports, and ADRs listed in the Medi-Span adverse drug effects databases, 
and is described in more detail in another paper (Harpaz, Vilar et al. 2013). 
3.2.3.2 Comparisons 
Four methods were compared with ours in this study: 1) a baseline method, which only used 
steps 1 and 2 of the proposed method where confounding was not considered 2) a knowledge-
based method where a knowledgebase, developed by clinical experts containing comprehensive 
non-drug related risk factors for rhabdomyolysis and pancreatitis was applied to exclude patients 
with predisposing conditions, which eliminated confounders from the population regardless of 
medication exposures. The rhabdomyolysis knowledgebase was previously established and is in 
the supplemental data of Haerian’s publication,(Haerian, Varn et al. 2012) and the one for 
pancreatitis is available in Table 3.2. After excluding patients with underlying conditions for 
developing ADRs, we performed step 2 of the proposed method. 3) the RF method proposed by 
Harpaz et al. was utilized where the shrinkage parameter was selected based on a conjecture that 
a size of between 20 and 40 conditions was reasonable, however, we used cross-validation  to 
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select the shrinkage parameter since this was more reproducible. 4) the PSM  proposed by 
Tatonetti et al was replicated, except that for each medication, we only used the top 200 




Table 3.2 Medical conditions that were found to be risk factors for pancreatitis 
UMLS ID UMLS PREFERRED TERM UMLS ID UMLS PREFERRED TERM UMLS ID UMLS PREFERRED TERM 
C0085762 alcohol abuse C0008340 choledochal cyst C0023891 liver cirrhosis, alcoholic 
C0001957 alcohol withdrawal delirium 
C0701818 Choledocholithiasis C0346647 
malignant neoplasm of 
pancreas 
C0236663 alcohol withdrawal 
syndrome C0008350 Cholelithiasis C0877425 mass of pancreas 
C0156076 alcoholic gastritis C0008370 Cholestasis C0333027 Microlithiasis 
C0001973 alcoholic intoxication, 
chronic C0009438 common bile duct calculi C0085407 Microsporidiosis 
C0267931 bile duct cysts C1397941 gallbladder  distension C0008313 cholangitis, sclerosing 
C0005411 biliary atresia C0860209 gallbladder sludge C0008320 cholecystectomy procedure 
C0242216 biliary calculi C0744257 gallbladder wall thickening C0008325 Cholecystitis 
C0151824 biliary colic C0521614 gallstone pancreatitis C0149520 cholecystitis, acute 
C0282074 biliary sludge C0019187 hepatitis, alcoholic C0947622 Cholecystolithiasis 
C0597984 biliary stricture C0020437 Hypercalcemia C0026780 Mumps 
C1167663 Biloma C0020502 Hyperparathyroidism C0400976 obliterative cholangitis 
C0206698 Cholangiocarcinoma C0020557 Hypertriglyceridemia C0747181 pancreas head mass 
C0008311 Cholangitis C0022354 jaundice, obstructive C0235974 pancreatic carcinoma 
C0030283 pancreatic cyst C0030297 pancreatic neoplasm C0566602 
primary sclerosing 
cholangitis 







3.3.1 Data collection and cohort characteristics 
Data was collected for 264,155 patients accounting for 6,221 unique generic drugs and 32,122 
unique medical conditions. The characteristics of patients who had rhabdomyolysis and 
pancreatitis are shown in Table 3.3. There were more men than women, and more African-
Americans than other ethnic groups developing rhabdomyolysis as expected because baseline 
CK levels are higher in men than in women, and higher in African-Americans than in the other 
groups (Neal, Ferdinand et al. 2009). There were almost equal numbers of men and women, and 
no ethnic predisposition for pancreatitis. There is no evidence that ethnicity or age affect the 
chance of developing pancreatitis (Santhi Swaroop Vege). 
Table 3.3 Demography of patient population 
Variable  Unique Patients Rhabdomyolysis Pancreatitis  
N  264,155  3,670  6,294  
Mean Age 
(±SD)  
50.9(±23.9)  57.6(±21.8)  57.9(±22)  
Sex  (Male)  42.5%  68.2%  50.3%  
Race (% of group)  
White  27.7%  26.1%  26.2%  
Hispanic  30%  22.4%  29.4%  
Black  14%  23.8%  19.3%  
Asian  2%  2.2%  2%  
Other/Undocumented  26.3%  25.5%  23.1%  
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3.3.2 Reference Standard 
Table 3.4 shows statistics and examples of the reference standard.  
Table 3.4 The statistics and examples of reference standard 
 Rhabdomyolysis  Pancreatitis  
Total # of drugs  618  436  
Examples  acetaminophen, simvastatin, 
candesartan, iotrolan  
amiodarone, omeprazole, 
meloxicam, zidovudine  
 
3.3.3 Statistics of detected drug-safety signals 
True positive signals signify that the signals are in the reference whereas false positive signals 
signify that those signals are not. Precision is measured as the ratio of true positive signals 
divided by the sum of true positive and false positive signals. Table 3.5 shows precision for the 
five methods. Among them, the proposed method performed significantly better than the other 
four methods for rhabdomyolysis, with a precision of 83.3% compared to 72.7% for PSM, 50% 
for RF, 58% for knowledge-based method and 38.7% for crude marginal association. For 
pancreatitis, the proposed method demonstrated similar precision compared with the PSM, as 
depicted by a precision of 60.8% and 66.2% respectively. The performance of the RF method 
was comparable to the knowledge-based method, and was worse than the PSM and the proposed 
methods. The knowledge-based method was significantly better than the baseline method, 
demonstrating that medical knowledge is effective in identifying confounders, but not as 
effective as the PSM and proposed models. The number of signals retrieved by each of the five 
methods is shown in Table 3.6. It is also apparent that the PSM had higher recall than the 
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proposed methods in terms of more signals detected. The upper bound of the recall for PSM and 
the proposed model were 0.15 and 0.02 for rhabdomyolysis respectively, and were 0.21 and 0.07 
for pancreatitis correspondingly.  








based method  







































 The number in the brackets is the confidence interval (CI) for the precision (p) 
ܫܥ ൌ ݌ േ ͳǤͻ͸ כ ට݌ כ ଵି௣௡  ,  n is the number of signals retrieved by a method 
* This precision can be improved to 70.5% [57.0%, 83.9%] by removing medications treating symptoms of 
pancreatitis 
 

























both to prescribe 
medications and 
develop ADR)  
Rhabdomyolysis  364  100  6  128  12  
Pancreatitis  666  437  7  142  51  
Table 3.7 lists the true and false positive signals obtained by the proposed method for 
rhabdomyolysis and pancreatitis. The false positive signals could be classified as due to 1) co-
medication confounding, 2) indication confounding, 3) comorbidity confounding, and 4) possible 
true signals not in the reference standard.  
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Table 3.7  ADR signals detected by the regression-based method and compared with reference standard 
 Rhabdomyolysis Pancreatitis  
TP  established  gemfibrozil, olanzapine, 
atorvastatin  
aluminum hydroxide, calcitriol, didanosine, furosemide, pentamidine, 
propofol, sulfamethoxazole, trimethoprim, lisinopril, stavudine, folate, 
lansoprazole, lamivudine, caspofungin, omeprazole, nelfinavir mesylate, 
imatinib mesylate  
plausible  aspirin, lorazepam, lisinopril, 
sulfamethoxazole, zidovudine, 
sirolimus, labetalol  
ergocalciferol, famotidine, fluconazole, gemfibrozil, nadolol, prednisone, 
sodium chloride, ondansetron, pantoprazole, mycophenolate mofetil, 
levofloxacin, atorvastatin, rabeprazole, esomeprazole,  
FP 
1 calcium acetate, 
mycophenolate mofetil 
NA 
2 NA clonidine, fentanyl,  meperidine, metoclopramide, norepinephrine, nystatin, 
simethicone, vancomycin, sodium acetate, calcium acetate 
3 NA insulin, nph insulin, ursodeoxycholate, ursodiol, midazolam, lorazepam 
4 NA levodopa, sildenafil citrate, lepirudin, sevelamer carbonate 
TP: true positive; FP: false positive; False positive signals are likely due to confounding by 1 co-medication; 2 indication; 3 co-
morbidity, and 4 possible true signals not in the reference standard. NA: not applicable
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3.4 Discussion 
Our results demonstrate that the proposed method is effective for dealing with confounders from 
EHR reports, and either outperforms or has similar performance as the four other comparators.  
3.4.1 Qualitative Analysis of Results 
3.4.1.1 False positive signals 
Only two false positive signals were obtained for rhabdomyolysis likely due to confounding by 
co-medication. For example, calcium acetate treats patients who have transplants or end stage 
renal disease, and consequently are on multiple drug regimens, such as prednisone and 
tacrolimus, both of which are known to cause rhabdomyolysis.  Our method currently does not 
handle confounding by co-medication, but will address it in future work.  
Among the false positive signals for pancreatitis, six were likely due to confounding by co-
morbidity.  For example, ursodeoxycholate and ursodiol are used to treat gallstones, common 
bile duct calculi, and biliary cirrhosis, which are risk factors for pancreatitis. After controlling for 
these confounders, the association still existed between pancreatitis and those two medications. 
This could be due to inherent limitations of EHR documentation, NLP errors produced during 
data preparation, or using incorrect time sequences in patients with only a single visit.   
The other 10 false positive signals, such as fentanyl, were likely due to confounding by 
indication. According to our criteria, these drugs should have been excluded as the exposures 
occurred after the ALS. However, for some cases the first measurement for amylase/lipase 
occurred after the drugs were ordered, which mainly happened because treatment for pancreatitis 
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was started based on early symptoms before the ALS was obtained, or because of the data 
characteristics, which is explained below. Such false positives are categorized in Table 3.8. 
Sevelamer carbonate, lepirudin, sildenafil citrate and levodopa are four candidates for which 
physicians could not find confounding or other reasons to relate with pancreatitis.   Further 
investigation of these drugs will be performed in future work. 
In this study, we compared results to a reference standard but did not look at individual cases to 
determine what the actual causes of the ADR were for the individual patients, therefore some 
true positive signals may be false when applied to patients.  
Table 3.8  Error analysis for false positive signals associated with pancreatitis 
Possible relationship with pancreatitis Medication 
Treatment for comorbidity of pancreatitis  
1. Treatment for gallstones that can cause pancreatitis ursodiol, 
ursodeoxycholate 
2. Treatment for stopping alcoholic abuse that can cause pancreatitis lorazepam, 
midazolam 
3. Treatment for hypertriglyceridemia that can cause acute pancreatitis 
or pancreatic problem induced diabetes mellitus 
insulin, nph insulin 
Treatment for symptoms of pancreatitis or pancreatitis-induced 
problems 
 
4. Treatment for pain associated with pancreatitis fentanyl, meperidine 
5. Treatment for pancreatitis-induced vasodilatory shock norepinephrine 
6. Treatment for pancreatitis-induced infections nystatin, vancomycin 
7. Treatment to reduce pancreatic juice secretion. It could be also used 
to treat a stress situation in pancreatitis with high catecholamine levels. 
clonidine 
8. Regulation of sodium and calcium disorders associated to pancreatitis sodium acetate, 
calcium acetate 
9. Used as an antiemetic in patients with pancreatitis. metoclopramide 
10. Reduction of bloating in patients with pancreatitis. simethicone 
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3.4.1.2 False negative signals 
False negative signals signify that the signals were not detected by the method but are in the 
reference standard. There were two reasons for false negative signals: insufficient data and over-
adjusting.  
Having a large enough set of patients is critical for detecting ADRs, especially rare cases 
(Makuch 2006). For example, in order to detect chloroquine-induced rhabdomyolysis (incidence 
rate between 3% and 5%), at least 100 patients must take this medication (Tisdale and Douglas 
2010). However, in our data set, there were only 37 patients on chloroquine. An insufficient 
number of patients for certain medications seemed to be the primary reason for false negatives.  
False negative signals also occurred due to over-adjusting, where the proposed method selected 
more confounders than it should have. For example, amlodipine, which causes pancreatitis 
between 1% and 4% of the time, was prescribed to 28,832 unique patients in our data, but the  
proposed method did not detect this since it adjusted for several superfluous confounders such as 
cytomegalovirus infection. In the future we will explore considering conditions based on smaller 
p-values to address this problem.  
3.4.2 The characteristic of the data set and the inherent nature of the two ADRs  
The results showed that the proposed method obtained better precision for rhabdomyolysis than 
for pancreatitis, which is due both to the characteristic of the data and to the nature of the ADRs. 
About 42% of the data set we used consists of patients with only a single visit. In such a case, 
when the ALS is reported, the corresponding clinical note frequently mentions the ADR, which 
is a diagnosis based on the ALS.  In that sense the ALS and ADR are synonymous, and the ADR 
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is not a confounding condition. For example, a patient with an elevated CK test is likely to have 
rhabdomyolysis mentioned in their note. Therefore, we eliminated use of the conditions 
rhabdomyolysis and pancreatitis respectively when they occurred in the note associated with the 
same hospitalization as the ALS.  The strategy worked well for rhabdomyolysis but not for 
pancreatitis because rhabdomyolysis is typically an acute event. In contrast, pancreatitis could 
also be chronic, and chronic pancreatitis may lead to an ALS, or a predisposition for acute 
episodes.  Therefore, removing mentions of pancreatitis reduced our method’s ability to detect it 
as a confounder, leading to reduction in precision for detecting the ADR pancreatitis. If the EHR 
included more instances of multiple visits, we should have been able to differentiate chronic 
from acute conditions. We subsequently explored the false positive medication signals by 
allowing pancreatitis to be a confounder if it met the criteria of confounding for category 2 and 3 
of Table 3.5, and eight false positive signals were removed which are displayed in Table 3.9, 
improving the precision of the  proposed method from 60.8% to 70.5% [57.0%, 83.9%].  
Although we were aware of the problem caused by single visits, we included them in the data set 
because it was critical to obtain as many medication events as possible.  Another difference 
between the two ADRs is that confounding by indication does not occur for rhabdomyolysis 
because medications are not used to treat it, but confounding by indication must be handled for 
pancreatitis since medications are used to treat it.  
Table 3.9   The eliminated drug safety signals after the post hoc analysis for the pancreatitis 
The category of false positive signals Medications 
2 clonidine, meperidine, metoclopramide, 
nystatin, simethicone, vancomycin 




3.4.3 Comparison of methods 
Apart from performance, the proposed method has the advantage of generalizability over the 
knowledge-based method. Generalizability is important because different facilities may have 
different populations.  For example, Ramirez et al identified burn as a major cause for 
rhabdomyolysis in their population;(Ramirez, Carcas et al. 2009) in contrast, Haerian et al found 
that myocardial infarction was a major cause for elevated Creatine Kinase (CK, the laboratory 
test for rhabdomyolysis) in their population (Haerian, Varn et al. 2012). Developing knowledge 
specific to each population requires that expertise and manual review of patient charts to select 
risk factors, which is costly. In comparison, the proposed method automatically identifies and 
adjusts for confounders. In addition, the proposed method determines confounders in a data-
driven fashion, which allows for finding proxy variables for the confounders, whereas the 
confounders must be predetermined when using knowledge. For example, in the association 
between aspirin and rhabdomyolysis, our method correctly identified ST-elevation myocardial 
infarction (STEMI) as a confounder (myocardial infarction also causes elevated CK), but also 
identified chest pain and increased sweating as confounders, which are common symptoms of 
myocardial infarction (MI). Our method was capable of adjusting for the confounding effect of 
MI using these proxy variables. Similarly, our method listed agitation and confusion as 
confounders of the association between lorazepam, which is used to treat cocaine abuse, and 
rhabdomyolysis. Cocaine abusers usually present with agitation and confusion, and are also 
associated with elevated CK (Warrian, Halikas et al. 1992). 
The proposed method has two advantages over the PSM. First, it has the power to detect drug 
safety signals when it mixes with the effect of comorbidity on the ADR outcome. For example, 
sevelamer is uniquely prescribed to patients on dialysis, which predisposes them to pancreatitis. 
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The PSM eliminates the effect of sevelamer on pancreatitis due to the effect of a variety of 
kidney problems, while the proposed method adjusts for the appropriate confounders including 
kidney failure, but retains the effect of sevelamer on pancreatitis. Another advantage is the 
informative clinical knowledge displayed by the confounders identified by the model. For each 
medication-ADR pair, the proposed method generates a set of confounders, which describes the 
effect or non-effect of a medication when taking several conditions into account. These 
conditions provide informative clinical knowledge useful for further analysis of the data. For 
example, chronic pancreatitis should have been a qualified confounder, but was missing from the 
pancreatitis model, as explained above. Therefore, we could re-analyze by including pancreatitis 
in the model. In contrast, the PSM is a black box and is not capable of providing insight 
concerning confounders. PSM has higher recall while lower precision than the proposed method. 
In terms of identifying true positive signals in the upper bound level, PSM identifies 83 and 63 
more signals than the proposed method for rhabdomyolysis and pancreatitis respectively. Higher 
recall is important for some ADR tasks, such as early ADR detection, but higher precision is 
important for others, such as re-ranking potential signals. 
 
3.4.4 Use of EHR narratives 
There are several advantages to using EHR narratives for detecting ADR signals. It is possible to 
obtain more comprehensive and finer grained medical information than the International 
Classification of Disease, Version 9 (ICD-9) codes assigned for billing purposes (Trifiro, 
Fourrier-Reglat et al. 2009, Ryan, Madigan et al. 2012).  Based on our data, patients had about 
46 medical conditions on average per year based on their notes, while they only had about 9 
ICD-9 codes on average per year. Moreover, had an ICD-9 code, such as cardiac valve fibrosis. 
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3.4.5 Limitations 
One limitation of this study concerns time intervals relevant to ADR detection. Currently, the 
method retrieved all medications prior to an ADR without considering time windows. For 
instance, a patient who took a drug in 2004 may have discontinued it in the same year, and may 
have developed an ADR in 2010.  Our method counted this patient in the case group but that 
time interval may be inappropriate. However, note that one general time window cannot be used 
for detecting all ADRs as previous studies have shown that the window between first drug 
exposure and the incidence of drug-induced pancreatitis can range between 1 and 1,000 days 
depending on the drug (Badalov, Baradarian et al. 2007). Also, we confronted the challenge of 
inadequate documentation or of an incomplete record of patients’ health events. 
Second, our method did not deal well with other confounding issues, such as protopathic bias, 
particularly when patients had only a single visit. Protopathic bias occurs when a drug is 
prescribed for an early manifestation of a disease that has not yet been diagnosed.  We plan on 
collaborating with researchers at other facilities to collect more longitudinal EHR data, which 
will allow us to obtain more  time information.    
Third, we used abnormal lab results as surrogates for determining rhabdomyolysis and 
pancreatitis, which is common in pharmacovigilance, but an abnormal CK could be due to 
strenuous exercise and not to rhabdomyolysis, and an increased amylase could be due to an 
inflamed parotid gland, and not to pancreatitis.  
3.5 Summary 
We proposed a novel data-driven method to control for the problem of confounding when using 
comprehensive EHR data, and demonstrated that the method achieved either a higher or similar 
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precision in detecting signals for two serious ADRs rhabdomyolysis and pancreatitis when 
compared to the four other methods while providing insight into confounders for each specific 
medication-ADR pair. This method is likely to perform better with a larger patient population 
with more longitudinal data, can be generalized to detect other ADRs while taking into account 






CHAPTER 4 A Study of the Effect of Data Characteristics on Adverse Drug Reaction 
Detection Algorithms in Pharmacovigilance 
 
4.1 Introduction 
In the United States, the Food and Drug Administration (FDA) maintains  the Adverse Event 
Reporting System (FAERS), consisting of suspected ADR case reports.  Among drugs 
mentioned in a case report, only one is assigned as primary suspected drug and others are 
assigned as secondary suspected, interactive, or concomitant drugs. Some case reports also 
provide indications for primary suspected medication and patient demographics. Indications and 
ADRs are coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
terminology. For example, the MedDRA term diabetes mellitus is encoded as an ADR for the 
medication diazoxide and as an indication for the medication sitagliptin. 
Automated methodology has become a standard tool to discover ADR signals from a collection 
of case reports (Hauben, Madigan et al. 2005, Harpaz, DuMouchel et al. 2012). 
Disproportionality analysis (DPA) is the main algorithm to detect ADRs, and quantifies the 
interestingness of each drug ADR pair in the data (van Puijenbroek, Bate et al. 2002, Zorych, 
Madigan et al. 2013). The most widely cited measurements include relative reporting ratio 
(RRR), reporting odds ratio (ROR), the geometric mean of empirical Bayes posterior distribution 
of the “true” RRR (EBGM) produced by Multi-item Gamma Poisson Shrinker (MGPS) and 
information component (IC) produced by Bayesian confidence propagation neural network 
(BCPNN). However, the above methods usually include drugs listed as primarily suspected of 
having caused an ADR without considering concomitant drugs (Caster, Norén et al. 2010, 
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Tatonetti, Patrick et al. 2012). This situation may vary and include concomitant medications in 
addition to primary suspected medications for the disproportionality analysis. Drugs usually 
listed as primary suspects may be reported more often for well-known ADRs. Additionally, these 
measures do not consider the impact of other variables, which may adversely affect signal 
detection. For example, indirect associations between a drug and an ADR may result when a 
drug is frequently co-reported with another drug that causes the ADR. For example, darunavir, 
which is not known to cause acute renal failure (ARF), is frequently co-prescribed with tenofovir 
disoproxil, which does cause ARF. An indirect association may also occur when a drug, such as 
acarbose, treats a condition leading to an increased risk for developing the ADR. For example, 
acarbose treats diabetes, which predisposes patients to developing ARF. These situations are 
known as confounding effects of variables not accounted for in the analysis. Therefore, a method 
that can adjust or control for confounding provided by co-medications and indications should be 
valuable for ADR detection. 
An adjustment by stratification to mitigate confounding effects was first proposed for pairwise 
associations, which adjusts for age, gender and reporting trend, in case that a particular drug may 
have different effects among patients with different ages (DuMouchel 1999).  Nonetheless, this 
is not feasible for moderate to large numbers of potential confounders and is only appropriate in 
the absence of effect modification, which occurs when the effect of two variables are dependent 
(DuMouchel 1999). Shrinkage regression, such as Bayesian logistic regression and L1 
regularization, has been proposed to deal with a large number of potential confounders such as 
confounding by co-reported medicines, and been demonstrated its success (Caster 2007, Caster, 
Norén et al. 2010). Another method, named propensity scores (PS), uses co-medications and 
indications to estimate each patient’s probability for the exposure of medication, and then 
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matches against the case control group based on these scores to mitigate the confounding effect. 
Tatonetti et al. used the PS method to detect drug-drug interactions in FAERS data, and 
demonstrated that the method mitigated the confounding effect by showing that the distribution 
of propensity score for prescribing a medication were balanced across different age and gender 
groups (Tatonetti, Patrick et al. 2012). Unlike other methods, this PS method considered not only 
primary suspected medications but also concomitant medications and indications. 
Currently, there is no such a study systematically examining the accurateness of primary 
suspected information delivered by reporters, and evaluating the effect on the ADR detection 
when considering primary suspected information only or overall information.  
This paper proposed a method of two-step LASSO regression to leverages primary suspected 
medications with concomitant medications and indications. We studied the above two questions 
by applying the proposed method and three other methods, which are frequency-based method, 
ROR and GPS, to two data sets: one is on the basis of primary suspected medications 
(indications for the proposed method), and the other is on the basis of primary suspected, 
secondary suspected and concomitant medications (indications for the proposed method).  
A reference standard was introduced as a benchmark against which four methods can be 
measured and consequently the studied questions can be answered. The reference standard is 
consisted of four ADRs: acute renal failure (ARF), acute liver injury (ALI), acute myocardial 
infarction (AMI) and gastrointestinal bleeding (GI bleeding), and provided by Observational 
Medical Outcomes Partnership (OMOP) group (Stang, Ryan et al. 2010)(Stang, Ryan et al. 
2010)(Stang, Ryan et al. 2010). The area under the receiver operating characteristic (ROC) curve 
(AUC) are the evaluation metric in this study, which are frequently used to evaluate accuracy of 
a statistical model (Manning, Raghavan et al. 2008), (DeLong, DeLong et al. 1988).  
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4.2 Method 
4.2.1 Study Setting 
This study used the publicly available FAERS database from 2004 to 2010.  Drugs are entered 
into a report using free text, which can be brand or generic names, while suspected ADRs are 
coded using MedDRA terms.  In order to gain statistical power, we normalize drug names to 
their chemical compounds using the STITCH database, which maintains synonym lists for 
chemicals, and relationships between drugs and their chemical compounds (Kuhn, von Mering et 
al. 2008). For example, quinapril hydrochloride and Hemokvin are mapped to the main 
ingredient quinapril. 
Two data sets were created to study the effect of primary suspected information on ADR 
detection. The first data set was consisted of primary suspected medications and their 
indications, and the second data set comprised the secondary suspected and concomitant 
medications in addition to those had been included in data set 1. The confounding information is 
represented by indications in data set 1 and signified by all medications and indications in data 
set 2. 
4.2.1 Methodology Framework 
The proposed method was based on a previously published work conducted by our group which 
included identifying confounders for specific medications using marginal odds ratios (ORs) and 
estimating the drug-ADR associations using a least absolute shrinkage and selection operator 
(LASSO) type regularization (Li, Salmasian et al. 2013). Results showed that the method 
outperformed the high-dimensional propensity score method, but the resulting false positive rates 
still exceeded the nominal level (Li, Salmasian et al. 2013). Therefore we revised the method in 
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two aspects: (1) in the previously work, we only considered the potential confounders that were 
significantly and positively associated with both the ADR and the medication. We now expanded 
this list to include medical conditions that were significantly associated with the ADR and 
medication in either a positive or negative direction. The rationale is that negatively associated 
conditions could also bias the strength of association. (2) Standard LASSO implicitly assumes a 
sparse structure in the covariates, and hence tends to select insufficient confounders in high-
dimensional regression, which in turn leads to inflated false positive rate. We adopted a two step 
LASSOs (Belloni, Chernozhukov et al. 2013)  for a better control of the false positive rate. In the 
first step, shown in formula 4.1, standard LASSO is applied to select a set of potential 
confounders associated with the ADR, denoted by ଵܵ; In the second step, shown in formula 4.2, 
LASSO type regression is used again to select medical conditions that are highly associated with 
the drug use, and denote them as ܵଶ. In both steps, we used 5-fold cross-validation to select 
LASSO penalties. Finally, we estimate the conditional association between the ADR and drug 
adjusting for all the confounders in ( ଵܵ ׫ ܵଶሻǤ  We then use one-sided p-values of the adjusted 
log odds ratios (log ORs) in the last step as the signal scores, shown in formula 4.3.  
Equation 4.1  The first step of two-step LASSOs 




Equation 4.2  The second step of two-step LASSOs 




ݓ ൌ ඥܾ݋ݎ݌ሺܴܦܣ ൌ ͳȁܴݔǡ ௜ሻܥ כ ሺͳ െ ܴܦܣሺܾ݋ݎ݌ ൌ ͳȁܴݔǡ ௜ሻሻܽ݊݀݅ܥ א ଵܵ 
 
Equation 4.3  The logistic regression model when controlling for all confounders 
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4.2.2 Comparators   
We used three different methods to compare with the proposed method. The first method, called 
FREQUENCY, is measured by the number of reports associated with a particular drug-ADR pair 
and then normalized by the total number of reports corresponding to the same ADR. A higher 
frequency for a particular drug-ADR pair represents more interestingness. The second is the 
lower limits of 95% Empirical Bayes Geometric Mean of RRR, called EB05 and the third is the 
lower 2.5th percentage of ROR distribution, called ROR05 Both the ROR05 and EB05 are DPA 
methods only using primary suspected information, however, EB05 takes sampling variance into 
account. ROR05 also represents unadjusted association - not controlling for confounders – of the 
proposed method.  
By comparing performances of different combinations of methods and data sets, we can study 
the accuracy of primary suspected information described by reporters in terms of whether they 
are confounded by indications and other medications besides the primary suspected one.  
4.2.3 Evaluation Metrics 
We use ROC and AUC to evaluate performance. An ROC is a graphical plot which illustrates 
performance of a scoring system as its discrimination threshold is varied (Fawcett 2006). To 
further compare different scoring systems we reduce ROC performance to a single scalar value 
representing expected performance by calculating the AUC (Huang and Ling 2005). Both 
metrics require ranking drug safety signals based on a specific association measurement. 
Therefore, we generate ranked signals for all the methods for evaluation. We also test the two 
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sided p-value for the hypothesis of no difference between two AUCs using DeLong’s non-
parametric approach for correlated ROCs (DeLong, DeLong et al. 1988). In order to make 
impartial comparison, the score of 0 is assigned to each drug-ADR pair in cases where there are 
no reports of explicitly corresponding to a specific drug ADR pair. However, if a drug ADR pair 
has never occurred together in the data set 2, it will be removed from the evaluation. 
4.3 Results 
4.3.1 Data characteristics 
In total, the accumulated data set from 2004 to 2010 in FAERS had 2,720,634 case reports. The 
reference standard includes 365 test cases whereas the drug and the ADR are mentioned together 
at least once. Table 1 shows the number of test cases for each ADR. 
Table 4.1  Number of test cases in the reference standard for each ADR 
ADR Positives Negatives 
ARF 23 52 
ALI 77 33 
AMI 34 59 
GIB 24 63 
4.3.2 AUCs for different methods and data sets 
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Table 4.2  AUCs for each combination of ADR, methods and data sets 
ADR Method PS Full 
AKI FREQUENCY 78.68 71.49 
 GPS 82.36 79.18 
 ROR05 82.53 79.93 
 AdjustedOR05 81.52* 84.03 
    
ALI FREQUENCY 88.63 80.20 
 GPS 86.58 75.48 
 ROR05 83.00 74.10 
 AdjustedOR05 83.16* 83.00 
    
AMI FREQUENCY 62.74 55.41 
 GPS 64.46 64.26 
 ROR05 64.31 65.35 
 AdjustedOR05 62.51* 67.65 
    
GI FREQUENCY 82.34 73.74 
 GPS 85.58 80.42 
 ROR05 87.96 80.75 
 AdjustedOR05 85.62* 80.75 
     PS: data consisted of primary suspected medications (indications is used only for AdjustedOR05) 
     Full: data consisted of primary suspected, secondary suspected and concomitant medications   (indications is used   
only for AdjustedOR05)  
    * AdjustedOR05 regards indications as potential confounders 
59 
Figure 4.1  AUCs of each method based on two different data sets for each ADR 
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4.4 Discussion 
4.4.1 Quality of primary suspected medication information 
Using only primary suspected medications leads to higher AUC performance but it is not 
significant than using overall medication information except for AdjustedOR05. FREQUENCY 
achieves fairly good performance compared with other statistical methods, which signifies that 
reporters are generally accurate when linking the ADR to its causative medication. ROR05 
accomplishes better AUC than adjustedOR05 indicating that confounding by indication is less of 
a problem in data set 1. However, the criteria for constructing the reference standard, such as no 
statistical evidence – EB05 > 2 (similar to ROR05 when sample size was big) – in FAERS for a 
negative test case, were correlated with tested methods and therefore could bias the results.  
The performance for lower 2.5 percentile of relative reporting ratio (RRR05) is almost identical 
to ROR05. EB05 is the Bayesian version of RRR05 and has the similar performance with 
ROR05 expressing that the issue of small sampling variance is not substantial in this study. 
All methods are more effective in identifying the other ADRs than AMI. No single method 
performed consistently better than the other methods for the 4 ADRs based on two data sets. 
4.4.2 Advantages of the proposed method 
AdjustedOR05 attains higher performance than ROR05 when applied to data set 2, which 
possibly demonstrates the existence of confounding by co-medication but it could also signify 
that the reference standard is less interrelated with ROR05.   
AdjustedOR05 is the best method among overall methods when using the full data set. In 
addition, it achieves comparable performance with the cutting edge method EB05 on the basis of 
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primary suspected medications. This is encouraging since AdjustedOR05 carries more 
information since quite a few drug ADR pairs (128 pairs) were tied to each other at 0 using 
information of primary suspected medication without sacrificing AUC performance.   
4.4.3 limitations 
One limitation of this study is that it uses a reference standard that is not independent from data 
and some statistical methods, which may predispose methods using primary suspected 
information to perform better. Moreover, confounding by unmeasured covariates remains a 
potential source of misinterpretation that should always be considered in the analysis of 
outstanding reporting patterns. Another limitation is that case reports in FAERS often contain 
inaccurate information. For example, some reports mentioned that patients took more than 20 
drugs, which may be caused by errors from reporters entering the medication history instead of 
the medications taken at the time of the report. Finally, we did not deal with duplicate reports, 
which are known to exist in FAERS and which could falsely lead to a signal. 
4.5 Conclusion 
This study adapts an existing method in a novel way to leverage primary suspected medications 
with concomitant medications and indications. By comparing performance with three other 
methods on different data characteristics, we demonstrated that the proposed method generally 
achieved comparable performance with the state of art GPS method. Methods using primary 
suspected information generally outperform methods that treat medications equally. However, no 
single method performed best in detecting all four ADR signals. 
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CHAPTER 5 A method to combine analyses from spontaneous reporting systems and 
observational healthcare data to detect adverse drug reactions 
 
5.1 Introduction 
Analysis of spontaneous reports of suspected ADRs has traditionally served as a valuable tool in 
the detection of previously unknown ADRs in post-market surveillance(Bate and Evans 2009, 
Harpaz, DuMouchel et al. 2012). However, because of well-known limitations of spontaneous 
reports, such as underreporting and biased reporting, reports (Alvarez-Requejo, Carvajal et al. 
1998), electronic healthcare data, such as electronic health records (EHRs) and administrative 
claims data, are starting to be used to complement the spontaneous reporting system (SRS) 
(Wang, Hripcsak et al. 2009, Stang, Ryan et al. 2010, Coloma, Schuemie et al. 2011, LePendu, 
Iyer et al. 2013). However, observational healthcare data has its own limitations such as 
confounding. Although both SRS and healthcare data represent unique challenges in their use, 
some researchers believe that they complement each other along several dimensions that may 
improve pharmacovigilance (Harpaz, DuMouchel et al. 2013, Patadia, Schuemie et al. 2014). 
Another challenge accompanied with the richness of information for pharmacovigilance practice 
occurs when these two resources provide conflicting or inconsistent information. Therefore, we 
propose a methodological framework to integrate analyses generated from the FDA Adverse 
Drug Event Reporting System (FAERS) and from healthcare data.  Harpaz et al’s method also 
combined signals from different sources but imposed the assumptions that the signals generated 
from each data source be on approximately the same scale, and be log-normally distributed 
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whereas our method does not impose these assumptions (Harpaz, DuMouchel et al. 2013). As 
part of the methodological framework, we incorporate a method to deal with confounding effect 
in NYP/CUMC EHR and the FAERS SRS. We apply the method to four clinically serious 
ADRs: acute renal failure (ARF), acute liver injury (ALI), acute myocardial infarction (AMI), 
and upper gastrointestinal bleeding (GIB) (Trifirò, Pariente et al. 2009) with an aim of 
demonstrating that signal detection performance can be improved by such an integrative strategy. 
The proposed integrative method is studied using three different experiments aimed at exploring 
the effect of data size and bias on the method: one where we combine FAERS with a single 
small-scale EHR database NYP/CUMC, one where we combine FAERS with a large-scale 
network-based EHR database GE, and one where we combine FAERS with a much larger-scale 
claims database. We further evaluate the proposed system under the scenarios that the two 
resources used in combining provide consistent/inconsistent information. 
5.2 Methodology 
5.2.1 Data Sources 
5.2.1.1 FAERS 
The data were extracted from FAERS from 2004 to 2010 encompassing 2.7 million reports, 
which comprised case reports mainly reported from pharmaceuticals, and to a lesser extent, from 
healthcare professionals and consumers . We preprocessed and mapped the free-text drug names 
to their ingredient level specification using the STITCH database(Kuhn, von Mering et al. 2008). 
The ADRs in FAERS were already coded using MedDRA preferred terms.  In this study, we did 
not utilize the explicit relationships between drugs and ADRs and considered all relationships as 
co-occurrence information. Consequently, we extended data to all medications mentioned in the 
case reports including primary suspected, secondary suspected and concomitant, as well as 
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indications. The signals from FAERS were obtained using the confounding adjustment method, 
which is presented in the Methods section of Chapter 4. 
5.2.1.2 NYP/CUMC EHR 
The data, consisting of 0.3 million patients, were extracted from the single-hospital EHR system 
at NYP/CUMC, after institutional review board approval. The data consisted of retrospective 
narrative records of inpatient and outpatient visits from 2004 to 2010, including admission notes, 
discharge summaries, lab tests, structured diagnoses in the form of International Statistical 
Classification of Diseases, Version 9 (ICD9) codes and structured medication lists. The majority 
of the data available for this study were from an inpatient population. Narrative reports were 
used to obtain the patients’ medications, and the structured ICD9 diagnosis codes were used to 
detect ADR events; these codes also served as surrogates of patient characteristics for 
confounding adjustment analysis. Similar as for FAERS, the signals from the EHR were 
computed using the confounding adjustment method proposed in this study, which is described 
in the Methods section of Chapter 4. 
5.2.1.3 GE EHR  
The EHR database, GE MQIC (Medical Quality Improvement Consortium), represents a 
longitudinal outpatient population of 11 million patients, and captures certain events in 
structured form that occur in usual care, including patient problem lists, prescription of 
medications, and other clinical observations as experienced in the ambulatory care setting. The 
data were analyzed systematically under OMOP using seven commonly used methods for 399 
drug-ADR pairs(Ryan, Stang et al. 2013). The resulting signal scores are reported and publicly 
available in OMOP. The signal scores for this database were computed using the optimal 
analytic method for each outcome as follows: self-controlled case series (SCCS) method for 
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ARF (analysis-ID 1949010), self-control cohort (SCC) method for ALI (analysis-ID 409002), 
and information component temporal pattern discovery (ICTPD) method for AMI and GIB 
(analysis-IDs 3016001 and 3034001) (Ryan, Stang et al. 2013). 
5.2.1.4 Claims data 
In this study, we obtained signal scores associated with the largest claims database, MarketScan 
Commercial Claims and Encounters (CCAE), which contains information on approximately 46 
million patients. Similar to the GE data, CCAE data were extensively analyzed in OMOP for the 
same drug-ADR pairs with various methods. The signal scores we used for this database were 
computed by OMOP using the SCC method for ARF, ALI and AMI (Analysis-IDs 404002, 
403002 and 408013), and the SCCS method for GIB (Analysis-ID 1931010) (Ryan, Stang et al. 
2013).  
5.2.1.4 Reference Standard 
The reference standard was developed by OMOP. It contains 165 positive and 234 negative 
controls, i.e., drugs for which there is or is no evidence for corresponding ADRs. This reference 
set was established by OMOP based on natural language processing (NLP) of structured product 
labels, systematic search of the scientific literature, and manual validation. The reference 
standard comprises 181 drugs and four clinically important ADRs: acute renal failure (ARF), 
acute liver failure (ALI), acute myocardial infarction (AMI), and upper gastrointestinal bleeding 
(GIB). More details about the reference standard data collection, including drug names, can be 
found in a previous publication (Ryan, Schuemie et al. 2013).  
Other important research conducted by OMOP resulted in establishment of varied ADR 
definitions, from narrow to broad, for each ADR outcome they studied (Harpaz, DuMouchel et 
al. 2013, Reich, Ryan et al. 2013). Furthermore, the mapping between ICD-9 codes and 
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corresponding MedDRA codes for each ADR outcome were also made available by OMOP. We 
adopted these definitions to identify ADR case groups in NYP/CUMC EHR and in FAERS. 
5.2.2  Cohort identification 
In this study, we used the broad definitions of ICD-9 codes established by OMOP for identifying 
ADR events in NYP/CUMC HER (Reich, Ryan et al. 2013). The same definitions were also 
utilized in the GE EHR and the claims database.  In addition, we used the corresponding 
MedDRA codes (as determined by OMOP) for FAERS to identify patients with a particular 
ADR. Our aim was to ensure that the ADRs are equivalent when using the different databases.  
5.2.2.1 FAERS 
Case reports, which have at least one applicable ADR MedDRA code for an ADR, were 
identified as a case group, whereas the rest were used as a control group. The indications and all 
the medications reported in case reports were included as candidate covariates for confounding 
assessment.   
5.2.2.2 NYP/CUMC EHR 
The four ADR case groups were identified using their equivalent ICD9 codes.  For each ADR, 
the control group consisted of those patients without the particular ADR.  A patient may have 
multiple records in an EHR and therefore may have experienced an ADR several times, and may 
have been on and off a particular medication. Only the first occurrence of an ADR was 
considered and candidate medications were restricted to those that were mentioned before the 
ADR. If a case patient did not have any medications mentioned before the ADR, or a control 
patient did not have any medication recorded before 2010, they were excluded from the analysis. 
We also applied a 180-day window before the latest medication prior to the ADR to retrieve 
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medications and medical conditions (ICD-9 diagnosis codes). We assumed that anything prior to 
that window are unlikely to be associated with the ADR. For example, a drug taken in 2004 
unlikely leads to the development of an ADR in 2010. For the control groups, we used the latest 
medication record before December 31st, 2010 as the anchor, and retrospectively drew a 180-day 
window to select medications and ICD-9 diagnoses. Since our patient population was dominated 
by inpatients with single hospitalization, the individual studying windows in the control groups 
were evenly distributed from 2004 to 2010. However, the temporality between medications and 
ADRs could be inaccurate since two types of information occur in the same visit note. Only 
ICD-9 codes were included as possible confounder candidates. Figure 5.1 illustrates the data 
extraction windows for cases and controls. 
Figure 5.1  EHR cohort identification and candidate covariates selection 
  










As illustrated in Figure 5.2, our methodology comprises three steps: (1) Obtaining the 
confounding adjusted signal score for each drug-ADR pair from individual health data; (2) 
Calibrating the signal scores based on the empirical distribution derived from a set of reference 
negative controls; (3) Combining calibrated signal scores from disparate databases. In what 
follows, we elaborate the technical details in each of the three steps. 
5.2.3.1 Obtaining confounding-adjusted ADR signal scores 
For FAERS and NYP/CUMC EHR, we generated signal scores, which are signified by one-sided 
p-values, using the adjusted log odds ratios (log ORs) and their standard errors calculated by the 
equations 4.1 - 4.3. 
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For GE EHR and claims data, the signal scores (one-sided p-values) were generated based on the 
log relative risks (log RRs) and their standard errors provided by their optimal methods.     
5.2.3.2 Standardizing ADR signal scores using p-value calibration 
If there is no drug-ADR association, the signal scores using one-sided p-value should be 
uniformly distributed over the interval (0, 1) in theory. In reality, that is often deviated and leads 
to an inflated false discovery rate. We apply the estimation algorithm to a set of negative controls 
in the reference standard, and estimate the empirical distribution of resulting signal scores 
following formula (5.1), where ݍ௜  represents a one-sided p-value of a negative control and n 
represents the number of negative controls in the reference standard.  ܨ௡෡ ሺݔሻ is then used as the 
null distribution to calibrate signal scores. This calibration was ADR specific by assuming that 
signal scores within similar groups have their inherent ranking. For example, a negative control 
for ALI was not considered in the calibration of AMI. This procedure could be considered as a 
supervised training procedure with the training set consisted of negative controls in the reference 
standard. Since we did not use the overall reference standard for both training data and testing 
data, over-fitting is less of a problem. 
Equation 5.1  P-value adjustment using empirical distribution based on negative controls of 
reference standard 






5.2.3.3 Combining ADR signals from two heterogeneous databases. 
Let ݌௜ଵdenote the ith ADR signal-score computed from source 1, (e.g. the NYP/CUMC EHR), 
and ݌௜ଶdenote the signal-score for the same drug-ADR pair computed from source 2 (e.g. 
FAERS). We used the formula 5.2 to combine the signal scores from the two data sources. 
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Equation 5.2  The composite signal calculated based on two equally contributed signals 
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5.2.3.4 Generalizing the combined method 
In this work, we combined the signal scores from multiple data sources with equal weights. This 
approach could be generalized to weighted combination. Formula 5.3 was used to compute a 
weighted combined signal, where the weights are proportional to their precision associated with 
the data set so that more weight was assigned when signal scores were more precise. 
Equation 5.3  The composite signal calculated based on two weightily contributed signals 










5.2.4 Evaluation Design 
We used the reference standard developed by OMOP as described above to generate three 
reference standards for our study. For reference standard 1, we restricted the evaluation to those 
drug ADR pairs for which FAERS contained at least one case report and the NYP/CUMC EHR 
contained at least five patients who were exposed to the studied medications and who were later 
diagnosed with the studied ADR. For reference standard 2, we restricted the evaluation to those 
drug-ADR pairs for which FAERS had at least one case report and the GE EHR had results 
available in the OMOP result set.  For reference standard 3, we restricted the evaluation to those 
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drug ADR pairs for which FAERS had at least one case report and the CCAE had results 
available in the OMOP result set.  
Based on reference set 1, 2 or 3, the performance of the combined system was compared against 
the performance of signal scores generated by each data source independently. Performance was 
measured using the area under the receiver operator characteristics (ROC) curve (AUC). To test 
if the differences of AUCs based on the different combination systems were statistically 
significant, we computed a one-sided p-value for the hypothesis that the difference between the 
AUC of the two systems was not equal to 0. The tests were computed using a bootstrapping 
method. To ensure the p-values were computed based on large enough samples of signal-scores, 
and to get a single answer representing all outcomes, the significant tests were based on overall 
reference sets used in each experiment.   
We further studied the nature and proper use of the combined system on the basis of four 
scenarios that could occur in actual pharmacovigilance practice where clinical assessors deal 
with frequently in their routine work. Using the cutoff p-value of 0.05, we considered a drug-
ADR pair as a signal if its p-value is less than 0.05. Accordingly, four scenarios are: (1) a drug-
ADR pair has p-value < 0.05 in both FAERS and healthcare databases meaning a consistent 
signal is exhibited in both sources, (2) a drug-ADR pair has p-value 0.05 in both data sources 
meaning the lack of this signal in either source, (3) a drug-ADR signal appears in FAERS but not 
in healthcare database meaning an inconsistent signal is exhibited and (4) a drug-ADR signal 
appears in healthcare database but not in FAERS also meaning an inconsistent signal is 
exhibited.  
We also compared the AUC before and after confounding adjustment on the basis of the FAERS 
and NYP/CUMC EHR respectively. Furthermore, we identified false positive signals in 
72 
NYP/CUMC EHR by selecting those negative controls that produced a one-sided p-value < 0.05 
in the confounding adjustment analysis. We identified false negative signals in EHR by selecting 
those positive controls that had a one-sided p-value > 0.05 in the confounding adjustment 
analysis.  In addition, we compared the AUC performance of the confounding adjustment 
method with the cutting-edge method Gamma Poisson Shrinkage (GPS) that produces signal 
scores signified by lower 5th percentile of the posterior observed-to-expected distribution 
(EB05) on the basis of FAERS data. The evaluation was restricted to those drug-ADR pairs for 
which FAERS had at least one case report. Furthermore we assigned a signal score value of 0, 
lowest possible signal score for EB05, to those drug-ADR pairs that were never mentioned as 
primarily suspected relationships, which consequently were not included in the analysis using 
GPS. 
5.3 Results 
We used 2.7 million case reports from FAERS, 0.3 million patients from the NYP/CUMC EHR, 
11 million patients from the GE EHR data and 47 million patients from the CCAE claims data. 
Some case reports were excluded from FAERS due to typos of drug names or/and the incomplete 
list of drug names using STITCH.  
Table 5.1 listed the number of positive and negative controls for the four ADRs when combining 
FAERS and the NYP/CUMC EHR, FAERS and the GE EHR, and FAERS and claims data 
respectively.  
Table 5.2 shows the AUCs with and without confounding adjustment, which suggests that the 
confounding adjustment was essential for both FAERS and NYP/CUMC EHR individually. 
Moreover, the AUCs after the confounding adjustment in FAERS were statistically significantly 
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better than those without the adjustment.  However, we did not observe a substantial 
improvement when using the NYP/CUMC EHR. In total, there were 4 false positive signals and 
35 false negative signals for the NYP/CUMC EHR. We display them correspondently in Table 
5.3 and Table 5.4.
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Table 5.1  Subsets of the OMOP reference standard used in the three experiments 
 
 
Reference Set 1 
FAERS & 
NYP/CUMC EHR 
Reference Set 2 
FAERS & 
GE EHR 
Reference Set 3 
FAERS & 
Claims data 
 P N P N P N 
Acute Renal Failure 16 37 21 48 21 51 
Acute Liver Injury 52 16 75 30 77 32 
Acute Myocardial Infarction 10 28 33 51 33 58 
Upper GI Bleed 17 38 24 57 24 63 
Total 95 119 153 186 155 204 
       P: positive controls in the reference standard; N: negative controls  
Table 5.2  AUC for FAERS and NYP/CUMC EHR before and after confounding adjustment 
ADR FAERS NYP/CUMC EHR 
 Unadjusted Adjusted Unadjusted Adjusted 
Acute Renal Failure 0.50 0.89 0.58 0.61 
Acute Liver Injury 0.50 0.70 0.55 0.45 
Acute Myocardial Infarction 0.48 0.65 0.44 0.53 
Upper GI Bleed 0.49 0.83 0.48 0.54 
Total 0.49 0.75 0.55 0.51 
 Unadjusted: signal scores (one-sided p-values) are not adjusted for the confounding effect 
 Adjusted: signal scores (one-sided p-values) are adjusted for the confounding effect 
 
Table 5.3  False positive signals in the EHR 
Medication ADR a B c D Pvalue1 Pvalue2
hyoscyamine GI Bleed 24 976 27614 2094848 0.00 0.00 
rosiglitazone GI Bleed 213 30123 27425 2065701 0.00 0.01 
hyoscyamine ALI 19 981 39029 2083433 0.00 0.01 
metaxalone AMI 81 2214 18371 2102796 0.09 0.04 
           a: number of patients exposed to the medication who developed the ADR 
           b: number of patients exposed to the medication who did not develop the ADR 
           c: number of patients not exposed to the medication who developed the ADR 
           d: number of patients not exposed to the medication who did not develop the ADR 
           pvalue1: unadjusted one-sided p-value 






Table 5.4  False negative signals in the NYP/CUMC EHR 
Medication ADR a B c d Pvalue1 Pvalue2 
amlodipine AMI 963 17010 4854 191352 0.00 1.00 
darbepoetin alfa AMI 134 2160 5683 206202 0.00 1.00 
dipyridamole AMI 102 1510 5715 206852 0.00 0.99 
nifedipine AMI 209 3490 5608 204872 0.00 0.17 
Acyclovir ARF 266 2631 14624 197082 0.00 1.00 
allopurinol ARF 725 2079 14165 197634 0.00 0.19 
Captopril ARF 400 1739 14490 197974 0.00 1.00 
cyclosporine ARF 352 907 14538 198806 0.00 1.00 
enalaprilat ARF 228 1191 14662 198522 0.00 0.85 
Ibuprofen ARF 756 32402 14134 167311 1.00 1.00 
Ketorolac ARF 164 5386 14726 194327 1.00 1.00 
Lisinopril ARF 2815 16984 12075 182729 0.00 0.98 
meloxicam ARF 103 1977 14787 197736 1.00 0.90 
Naproxen ARF 256 6767 14634 192946 1.00 1.00 
allopurinol ALI 164 2926 5935 203323 0.00 1.00 
ciprofloxacin ALI 222 4892 5877 201357 0.00 1.00 
cyclosporine ALI 178 1117 5921 205132 0.00 0.94 
Diltiazem ALI 224 5814 5875 200435 0.00 1.00 
fluconazole ALI 330 4845 5769 201404 0.00 1.00 
Ibuprofen ALI 545 30766 5554 175483 1.00 1.00 
Ketorolac ALI 125 5120 5974 201129 0.98 1.00 
lamivudine ALI 126 1204 5973 205045 0.00 1.00 
levofloxacin ALI 591 11486 5508 194763 0.00 1.00 
Lisinopril ALI 738 19117 5361 187132 0.00 1.00 
Naproxen ALI 134 5921 5965 200328 1.00 1.00 
nifedipine ALI 150 3742 5949 202507 0.00 0.98 
Ramipril ALI 139 3562 5960 202687 0.00 0.99 
citalopram GI BLEED 246 4250 6437 202220 0.00 1.00 
clopidogrel GI BLEED 542 12940 6141 193530 0.00 1.00 
escitalopram GI BLEED 188 3616 6495 202854 0.00 0.72 
Ibuprofen GI BLEED 492 27177 6191 179293 1.00 1.00 
Ketorolac GI BLEED 105 4813 6578 201657 1.00 1.00 
Naproxen GI BLEED 168 5052 6515 201418 0.36 1.00 
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potassium chloride GI BLEED 154 2778 6529 203692 0.00 1.00 
Sertraline GI BLEED 256 4850 6427 201620 0.00 0.85 
a: number of patients exposed to the medication who developed the ADR 
b: number of patients exposed to the medication who did not develop the ADR 
c: number of patients not exposed to the medication who developed the ADR 
d: number of patients not exposed to the medication who did not develop the ADR 
pvalue1: unadjusted one-sided p-value 
pvalue2: adjusted one-sided p-value 
 
 
The results from experiment 1 are presented in Table 5.5. We found that the FAERS system 
performed significantly better than the NYP/CUMC EHR system. Combining FAERS and 
NYP/CUMC EHR data did not improve the ADR detection performance of FAERS, although it 
did not harm it either. The combined system still performed significantly better than the 
NYP/CUMC alone. Experiment 2, which is also presented in Table 5.5, shows that the combined 
system outperformed both the FAERS and the GE EHR individual systems. Improvements were 
observed for all the outcomes, although at different levels. The AUC of the combined system 
ranged from 76% for ALI to 92% for ARF. For individual systems, the GE EHR system had 
better AUC performance for AMI than FAERS, but worse than FAERS for ARF, ALI and GIB. 
Similar results were found when combining FAERS with the CCAE in experiment 3. The CCAE 
had better performance than FAERS for AMI and GIB, but was worse for the other two.  Again, 
the combined system outperformed the individual ones for all the four outcomes.  
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Table 5.5  AUC of signal detection performance for FAERS, healthcare data and combined 
systems 
 Experiment 1. Combining FAERS and NYP/CUMC EHR 
ADR FAERS EHR Combined 
Acute renal failure 0.89 0.61 0.89 
Acute liver injury  0.70 0.45 0.68 
Acute myocardial 
infarction 
0.65 0.53 0.70 
Upper GI bleeding 0.83 0.54 0.83 
Total 0.75 0.51 0.74 
 
 Experiment 2. Combining FAERS and GE EHR 
ADR FAERS GE Combined 
Acute renal failure 0.91 0.68 0.92 
Acute liver injury  0.71 0.63 0.76 
Acute myocardial 
infarction 
0.72 0.80 0.82 
Upper GI bleeding 0.80 0.77 0.87 
Total 0.76 0.76 0.82 
 
 Experiment 3. Combining FAERS and the claims data 
ADR FAERS Claims Combined 
Acute renal failure 0.91 0.83 0.93 
Acute liver injury  0.72 0.69 0.79 
Acute myocardial 
infarction 
0.71 0.77 0.82 
Upper GI bleeding 0.81 0.83 0.86 
Total 0.76 0.78 0.82 
 
 
Results in Table 5.6 shows that the combined system achieved better AUC performances in most 
of four scenarios for two of the combination studies. Specifically, when compared with the better 
performing individual system, the combined system increased AUC improvement ranging from 3% 
to 11% although it decreased the one of 7% whereas the signals exhibit in FAERS but not in 
claims database. The difference of AUC performance was defined as the AUC of combined 
system minus the AUC of better performing individual system.  
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Table 5.6  The AUC performance of FAERS, healthcare data and the combined system on the 
basis of four scenarios 
 Consistent information in two sources Inconsistent information in two sources 










database does not 
Healthcare 
database shows 




25/0 61/152 29/11 38/23 
FAERS alone NA 0.71 0.73 0.60 
GE alone NA 0.69 0.78 0.68 
FAERS and GE 
combined 
NA 0.75 0.89 0.68 
     
Positive/negative 
controls* 
49/3 16/104 7/8 83/89 
FAERS alone 0.84 0.68 0.68 0.67 
Claims alone 0.69 0.50 0.86 0.67 
FAERS and Claims 
combined 
0.89 0.74 0.79 0.68 
*Positive and negative controls are defined according to the reference standard 
Signals are identified based on one-sided p-value < 0.05  
NA: AUC performances are not computable when only positive controls are available 
 
Using the cutoff p-value of 0.05, we evaluated the precision and recall of the two combined 
systems – the combination system using FAERS and GE EHR, and the combination system 
using FAERS and claims data. Combining FAERS with the GE EHR resulted in higher recall 
(0.41 versus 0.35), while the precisions of the two combination systems were almost identical 
(0.925 versus 0.931).  Using the same cutoff p-value, eight more signals were detected only by 





Table 5.7   ADR signals detected only using the combined GE and FAERS system and their one-
sided p-values in three systems 
medication ADR Ground Truth FAERS GE Combined system 
piroxicam ARF 1 0.299 0.432 0.043 
amoxapine AMI 1 0.076 0.118 0.007 
diflunisal AMI 1 0.109 0.192 0.007 
eletriptan AMI 1 0.682 0.072 0.034 
nabumetone AMI 1 0.079 0.494 0.035 
nelfinavir AMI 0 0.292 0.263 0.044 
zolmitriptan AMI 1 0.224 0.381 0.034 
ketorolac GIB 1 0.425 0.069 0.041 
 
Figure 5.3 shows the histograms of the signal scores for upper GI bleeding in each experiment. It 
is apparent from the figure that the scale of signal score for FAERS did not overlap substantially 
with each healthcare data set, and the distribution of the signal scores did not follow a normal 
distribution.   
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Figure 5.3  Histograms of signal scores when combining FAERS with the three healthcare data 
sets 
 
Signal scores for FAERS and the EHR are signified by log OR, and signal scores for the GE EHR and the claims 
data are signified by log RR. 
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5.4 Discussion  
The main results of our evaluation show that combining signals from two relatively large data 
sources (e.g. FAERS and the GE EHR data, FAERS and the claims data) using the proposed 
methodological framework led to an overall significant improvement, which was replicated for 
the different outcomes. However, we did not observe the improvement when combining FAERS 
with the NYP/CUMC EHR. The discrepancies are possibly attributed to issues such as small data 
size and sample biases. 
5.4.1 Small data size 
NYP/CUMC EHRs have already been successfully used for detecting safety signals in several 
studies (Schneeweiss, Rassen et al. 2009, Coloma, Schuemie et al. 2011, Gagne, Glynn et al. 
2012). However, challenges remain because of the relatively small size of the data. There were 
only 0.3 million patients in NYP/CUMC EHR compared with 11 million in GE EHR and 47 
million in the claims data. Since ADRs generally occur infrequently in the EHRs, and their 
signals are often weak, a large data size is essential for effective detection.  
For the same reason, we could clearly observe that higher prevalence of an ADR resulted in 
better performance on the basis of the NYP/CUMC EHR. Specifically, NYP/CUMC EHR 
included 14,890 patients having ARF, 6,099 patients having ALI, 5,817 patients having AMI, 
and 6,683 patients having upper GI Bleed.  ARF with many more patients, almost three times as 
many patients than those developing AMI, had better AUC performance than the other three 
ADRs. Furthermore, when using NYP/CUMC EHR to detect the drugs associated with ARF, we 
achieved 100% precision, and successfully identified three true positive medications, 
hydrochlorothiazide, telmisartan and candesartan.  
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5.4.2 Sampling biases 
The NYP/CUMC EHR data came from a tertiary care academic medical center in a major 
metropolitan inner city area, which may lead to a highly skewed population. In addition, many of 
the patients included in our analysis could have been referred from other facilities and therefore 
their EHR data may have been incomplete because it may have lacked longitudinal information 
for many of those patients. Namely, only 37% of patients had at least one outpatient visit and 
only 14% of patients had more than one visit. Moreover, NYP/CUMC EHR data was not linked 
to pharmacy prescriptions or refills, and the medications extracted from free-text notes were just 
the mentions of medications, and therefore temporal relationships between medication exposures 
and ADR events may not have been definitive. In contrast, the GE EHR represented a large 
outpatient population and captured longitudinal patient information, such as ICD-9 coded 
medical problems and prescriptions. The claims data represented a much larger and more diverse 
population, and captured longitudinal patient information including diagnosis codes for billing 
purposes, as well as dates when prescriptions were filled or refilled. However, both the GE EHR 
and the claims data may also have faced the challenge of a skewed patient population, such as 
sicker patients having much more visits, and more prescriptions and refills in the database (Ryan, 
Madigan et al. 2012).  
5.4.3 Usefulness for pharmacovigilance practice 
The AUC evaluation showed that FAERS had substantially better performance for ARF and 
ALI, and worse performance for AMI than healthcare data, which indicates that no single source 
may provide best evidence for all ADR detections. Therefore, synthesis of evidence from 
multiple streams of information is extremely significant. Currently, clinical assessors carry out 
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the analysis of evidence from multiple sources. For example, clinical assessors may validate or 
want to evaluate a signal from different resources, as those generated from SRSs and/or 
healthcare data. Thus, a common situation that clinical assessors need to deal with is inconsistent 
or conflicting information from the different data sources.  
Results show that the combined ADR signals generated by the proposed method improved the 
AUC performance significantly compared with individual systems. In addition, we evaluated the 
combined system in four scenarios: (1) signals were demonstrated in both FAERS and the 
healthcare data; (2) no signals were generated in FAERS and in the healthcare data; (3) signals 
only appeared in FAERS but not in healthcare database and (4) signals only appeared in 
healthcare database but not in FAERS. We observed the consistent improvement was achieved 
by the combined system except for when signals appeared in FAERS but not in claims database. 
However, the combined system was still better than FAERS system alone in ranking potential 
signals. Therefore, the proposed system could serve as a tool for clinical assessors when they 
review ADR cases. For example, in the scenario of consistent signals, clinical assessors are more 
likely to believe the existence of the signals and may want to select the strongest signals for 
further assessment; the combined system could prioritize signals by integrating the two sources. 
In the scenario of inconsistent signals, the combined system is able to resolve inconsistent or 
conflicting statistical information and then provide a single response through the consolidation of 
statistical information from the two sources. In the scenario where no single source provides a 
signal, the combined system could possibly transfer two relatively weak signals into a stronger 
composite one. For instance, eight more signals were detected only using the combined GE and 
FAERS system and seven of them were true positives, which is promising. However, a practical 
challenge is how to effectively communicate these results to the clinical assessors. In addition, 
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combining FAERS with GE resulted in higher recall and almost identical precision when 
compared with combining FAERS with claims data. We also observed that healthcare databases 
were more sensitive for ADR detection than FAERS in terms of identifying more signals. We 
acknowledge that the recall and precision are threshold-dependent performance metrics. Hence 
the results may vary when using different thresholds.  
5.4.4 Related work 
Our method was designed originally to combine the NYP/CUMC EHR with FAERS, which is 
the first such study. Harpaz et al designed an empirical Bayes model to combine signals across 
FAERS and claims data showing its effectiveness using the same reference standard used in this 
study. However, that method required that the data satisfy two assumptions: a) the signal-scores 
generated from each individual data source should be on approximately the same scale, and b) 
the scores should follow the log normal distribution. Our data sets did not meet these 
assumptions. Figure 5.3 illustrates the violation of the above two assumptions for upper GI 
bleeding, but the other three ADRs had similar results.  
5.4.5 Methods to deal with confounding 
The capability to reduce or eliminate confounding is a major aim of ADR detection. Self-
controlled designs have recently been proposed and successfully utilized in ADR detection based 
on longitudinal healthcare data. They attempt to identify equivalent periods of unexposed time 
within the same patients, against which to compare the same patients’ exposed time. However, 
NYP/CUMC EHR data lacked this kind of longitudinal information relating to when a patient 
was put on or taken off a medication. Our prior study showed that insufficient confounder 
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selection led to high false positive rates (Li, Salmasian et al. 2013)  and therefore we designed 
the two-step LASSO regression (step 1 of the proposed methodological framework) to select 
more associated confounders. The AUC performances were generally improved after the 
confounding adjustment except for ALI.  We also applied this algorithm to the FAERS data and 
the AUC performances were statistically significantly better with this algorithm than without it. 
Furthermore, results in Table 5.8 shows that the confounding adjustment method achieved 
comparable performance with the cutting-edge algorithm GPS based on FAERS. For example, 
the confounding adjustment method had better AUC performances in ARF, AMI and GIB㸪and 
lower AUC performance in ALI. The advantage of the two-step LASSO compared with the 
single LASSO is shown in Figure 5.4 and Figure 5.5, where the two-step LASSO separated 
positive controls more from negative ones, reduced the false positive rate and achieved better 
AUC performance.  
Table 5.8  Reference set and the AUC performance for the confounding adjustment method and 
Gamma Poisson Shrinkage (GPS) method on the basis of FAERS from 2004 to 2010 
 Reference set  AUC performance 
 Positive Negative Confounding adjustment 
method (p-value) 
GPS (EB05) 
Acute renal failure 23 52 0.90 0.76 
Acute liver injury 77 33 0.72 0.87 
Acute myocardial infarction 38 59 0.72 0.70 
Upper GI bleeding 24 63 0.81 0.79 
 
Figure 5.4  Comparison between single LASSO and double LASSO on the basis of the EHR for 




Figure 5.5  Comparison between single LASSO and double LASSO on the basis of the FAERS 
for acute renal failure 
 
5.4.6 False positive signals in CUMC/NYP EHR 
One false positive signal was rosiglitazone for GI Bleed. Rosiglitazone was mentioned on the 
records of 1,587 patients where 133 of the patients developed GI Bleed. The confounding 
adjustment method scored this pair with a one-sided p-value of 0.01. In contrast, pioglitazone is 
in the same drug class, and was mentioned in the records of 2,477 patients where 110 patients 
developed GI bleed. The confounding adjustment method scored this pair with a one-sided p-
value of 1.  
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5.4.7 False negative signals in CUMC/NYP EHR 
Ryan et al demonstrated that the cohort method using high dimensional features selected by 
Bayesian logistic regression generally yielded a negatively biased estimate (Ryan, Stang et al. 
2013). We observed the same trend in our data set and summarize possible reasons for false 
negative signals: 1) Data sparseness since there were not enough patients exposed to the studied 
medications while the ADR occurrences were quite rare. 2) Confounding by indication. It is 
common that the indication for a drug may bias the estimated association if it is associated with 
an increased risk of the ADR itself. For example, amlodipine and nifedipine have hypertension 
as an indication, but hypertension was also related to AMI, and therefore did not produce 
positive associations. However, amlodipine and nifedipine were in the reference standard as 
being positive for AMI. The proposed method could not deal with this issue correctly, and more 
clinical knowledge may be needed. For example, we may compare a medication with the other 
medications having the same treatment regime to better understand its relationship with the 
ADR.  
5.4.8 Generalized the combined method 
The results of Table 5.9 demonstrated that equally combined strategy outperformed the weighted 
combined strategy. However, the performance may vary when apply to different signal scores 
generated from different data sources. The value of using equally combined strategy is that it 
overcomes the problem existing in the weighted combined strategy when one of the data sources 
being considered is much larger than the others, in which case it may dominate the weighting for 
certain associations. In addition, the substantial improvement of the combined system after p-
value calibration demonstrated that the empirical calibration is needed to correct p-values. The 
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overall AUC performance for CCAE or GE was worse after the p-value calibration because quite 
a few calibrated p-values were tied to each other. 
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Table 5.9  AUC of signal detection performance for the equally and weighted combined systems 
ADR Unstandardized ADR signal scores Standardized ADR signal scores 
 Experiment 1. Combining FAERS and the EHR 
 FAERS EHR Equally Weighted FAERS EHR Equally Weighted
Acute renal 
failure 
0.89 0.61 0.89 0.88 0.89 0.62 0.89 0.89 
Acute liver 
injury  




0.65 0.53 0.70 0.67 0.66 0.53 0.70 0.68 
Upper GI 
bleeding 
0.83 0.54 0.84 0.82 0.84 0.54 0.83 0.81 
Total 0.75 0.51 0.75 0.75 0.75 0.52 0.74 0.73 
 Experiment 2. Combining FAERS and the GE EHR 
 FAERS GE Equally Weighted FAERS GE Equally Weighted
Acute renal 
failure 
0.91 0.68 0.87 0.80 0.91 0.69 0.92 0.88 
Acute liver 
injury  




0.72 0.80 0.80 0.80 0.73 0.80 0.82 0.83 
Upper GI 
bleeding 
0.8 0.77 0.83 0.83 0.81 0.78 0.87 0.87 
Total 0.76 0.76 0.82 0.77 0.77 0.71 0.82 0.82 
 Experiment 3. Combining FAERS and the claims data 
 FAERS Claims Equally Weighted FAERS Claims Equally Weighted
Acute renal 
failure 
0.91 0.83 0.88 0.80 0.92 0.83 0.93 0.93 
Acute liver 
injury  




0.71 0.77 0.77 0.74 0.72 0.77 0.82 0.76 
Upper GI 
bleeding 
0.81 0.83 0.83 0.82 0.81 0.84 0.86 0.85 
Total 0.76 0.78 0.81 0.76 0.77 0.73 0.82 0.80 
Standardized: signal scores are standardized using p-value calibration with the empirical null 
distribution derived from negative controls of the reference standard 
Equally: equally combined system  




This study had several limitations. First, using the NYP/CUMC was a limitation because of its 
relatively small population, which limited EHR signal detection capability, and therefore 
performance of the combined system as well. In future work, we plan to include additional EHR 
data from multiple sites. Second, the NYP/CUMC data is mainly dominated by inpatient data so 
that acquiring comprehensive and longitudinal patient information is a challenge. Second, when 
using the NYP/CUMC EHR, we simply adopted the OMOP outcome definitions, which may not 
be optimal for the EHR data set, and could have lead to outcome misclassification including both 
false positive and false negative patients. Third, the confounding adjustment method did not deal 
well with drugs given only to a particular patient population and therefore the control groups on 
the basis of a general population were not representative for that population.  Therefore selecting 
patients having the same indications may be more appropriate. Fourth, when using FAERS, we 
did not remove duplicate reports or correct terminological errors. Lastly, the reference standard 
consists of test cases that were publicly known during the time frame of our evaluation, and thus 
the performance may be different when applied to actual clinical care. For example, physicians 
may be less likely to prescribe those drugs during the study timeframe because they already were 
aware of the ADRs.  
 
5.5 Conclusion 
In this paper, we described a method for ADR detection that combined FAERS with healthcare 
data and showed significant improvement when individual healthcare resources had sufficient 
amounts of data. Although the small NYP/CUMC EHR database did not contribute to 
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improvement, use of the large-size network-based GE EHR data and claims data did significantly 
show improved performance when combined with the FAERs data. An advantage of this method 
is that it can serve as a tool for synthesizing evidence for clinical assessors in actual 
pharmacovigilance practice.  
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CHAPTER 6 Summary and Conclusions 
 
6.1 Summary 
This dissertation has proposed and investigated three sequential hypotheses in order to 
demonstrate that a framework that computationally integrates ADR evidence from multiple data 
sources is feasible and efficient for ADR detection. The three hypotheses are: (1) a data-driven 
method could achieve comparable or slightly higher accuracy than those trained with experts and 
existing automatic methods; (2) a data-driven and regression-based method using primary 
suspected, secondary suspected, concomitant medications and indications could accomplish 
comparable or slightly better accuracy than the cutting edge algorithm Gamma Poisson 
Shrinkage (GPS) using primary suspected medications only; (3) a computational integration 
method could result in a more accurate ADR detection system than individual systems based on 
either FAERS or observational healthcare data. 
The first hypothesis involved research concerning a data-driven and regression-based method for 
alleviating confounding effect in ADR detection using a single facility EHR database. Results 
showed that precision of ADR detection was 83.3% for rhabdomyolysis and 60.8% for 
pancreatitis when using the proposed method, and it identified several drug safety signals that are 
interesting for further clinical review.  Compared with four comparators, the proposed method 
achieved either a higher or similar precision, and had the unique ability to provide insight into 
confounders for each specific medication–ADR pair, and could be easily adapted to other EHR 
systems. 
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The second hypothesis improved the performance of ADR detection by using information of 
concomitant medications and indications in additional to primary suspected medications 
commonly utilized by the disproportionality analysis. We proposed the use of two-step Lasso 
regression to select sufficient confounders and then to estimate the associations when adjusting 
for these confounders. The overall goal was to alleviate the confounding effect due to co-
medications and indications. Evaluation indicated that two-step Lasso regression improved AUC 
for acute renal failure and acute myocardial infarction, but not for the other two, compared with 
the well-established Gamma Poisson shrinkage method. Since the reference standard is explicitly 
correlated with GPS for negative controls, the performance of GPS is over estimated.  
Finally, the third hypothesis involved a computational method of integrating ADR evidence from 
multiple data sources, which was explored and resulted in a more accurate ADR detection 
system. In the study, we proposed an algorithm to combine signal scores of one-sided p-value 
mined from SRS and observational healthcare databases. Evaluation based on reference 
standards consisting of known positive and negative test cases indicated that although there was 
no improvement in the AUC when combining the SRS and small-scale EHR, the AUC of the 
combined SRS and large-scale EHR was 0.82 whereas it was 0.76 for each of the individual 
systems. Similarly, the AUC of the combined SRS and claims system was 0.82 whereas it was 
0.76 and 0.78 respectively for the individual systems. Furthermore, the combined system can 
serve as a tool in actual pharmacovigilance practice to either consolidate consistent information 
or resolving inconsistent information provided by different data sources, and the combined 




6.2.1 Contributions to Biomedical Informatics 
1. The major contribution of this dissertation research to biomedical informatics is that it 
develops a framework to combine ADR evidence from multiple data sources and 
demonstrates the framework significantly improved performance of ADR detection using 
three experiments involving combining the SRS with a single facility EHR, a larger-scale 
network-based EHR, and a much larger-scale healthcare claims database.  
2. The proposed framework requires obtaining and measuring signal scores using the most 
appropriate methods for each individual data sources and are in the form of one-sided p-value. 
We developed a data-driven and regression-based method to acquire signal scores from both 
a single facility EHR system and FAERS, which are proven to be better or comparable with 
other existing methods.  
3. The method to combine ADR data from multiple data sources can be generalized to 
integrate evidence from other data sources. For example, using biomedical literature and 
disproportionality analysis to generate ADR signals is another promising direction. The 
signal scores could be transferred into one-sided p-values and be integrated into the 
combinational method. 
4. The proposed LASSO and two-step LASSO methods together with the feature screening 
are data-driven methods so that they could be easily adapted to other EHR systems for ADR 
detection. Moreover, the methods can be generalized to other tasks such as discovering drug 
off-label use on the basis of EHR data. 
6.2.2 Contributions to Healthcare 
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The primary contribution of this dissertation research to healthcare is that it develops an 
automated system for computationally integrating ADR evidence from heterogeneous sources 
improving performance of ADR detection. Furthermore this combined system can serve as a tool 
for assisting manually review process. The synthesis of evidence from multiple streams of 
information has been an integral part of pharmacovigilance. Yet, it is currently carried out by 
clinical assessors on an ad hoc basis, in a rather qualitative manner, and usually after a signal is 
generated. The proposed system can prioritize ADR signals when signals are demonstrated 
consistently in multiple data sources, resolve conflict information when signals are demonstrated 
in one data source but not in the other data source, and detect ADR signals that are not able to be 
detected using individual data sources.  
6.3 Innovations 
The proposed approach is the first real attempt to computationally integrate ADR evidence from 
SRS and EHR databases in the field of pharmacovigilance. 
1. To the best of my knowledge, this is the first time that a computational method of 
integrating ADR evidence, from an SRS and an EHR, has been developed for achieving 
higher accuracy of ADR detection compared with individual systems in 
pharmacovigilance.  
2. For the first time, the evaluation has been conducted on the basis of scenarios where two 
data sources provide consistent or inconsistent information. 
3. It is novel that data-driven and regression-based methods have been developed to identify 
confounders and estimate drug-ADR associations when adjusting for these confounders. 
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6.4 Limitations 
Some specific limitations have been described in previous chapters, and are summarized below: 
1. The NYP/CUMC EHR data is one of major data sources used in this dissertation, 
however, the performance of ADR detection when combining the FAERS with this 
particular EHR system was not improved. The reason is that the NYP/CUMC EHR data 
came from a tertiary care academic medical center in a major metropolitan inner city area, 
which may lead to a highly skewed population. In addition, many of the patients included 
in our analysis could have been referred from other facilities and their EHR data may 
have been incomplete because it may have lacked longitudinal information for many of 
those patients. Therefore, temporal information, which is critical for drug-ADR detection, 
is not well represented in the collected data. Moreover, NYP/CUMC EHR data was not 
linked to pharmacy prescriptions or refills, and the medications extracted from free-text 
notes were just the mentions of medications, and therefore temporal relationships 
between medication exposures and ADR events may not have been definitive. In addition, 
NYP/CUMC EHR data is relatively small compared with other data sources.  
2. The method involving signal score calibration currently relies on the availability of 
reference negative controls for a particular ADR, which is hard to be generalizable to 
other ADRs. 
3. The development and evaluation of evidence-based methods require benchmarks for 
signal detection performance, and therefore we used published reference sets to evaluate 
all proposed systems. However, it should be noted that the reference standards consisted 
of established ADRs without evidence for or against causal associations with a drug, and 
the emerging ADRs are different from established ADRs in nature. Therefore, the 
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performances evaluated based on the reference standards used in this dissertation are 
retrospective but not prospective which could possibly yield different conclusions.  
4. The proposed combined system delivers the evidence in a very concise format, namely, a 
single index ranging from 0 to 1. However, there is not an established threshold for this 
index to determine whether a particular drug ADR pair is a potential signal. In addition, 
although the combined system could discover ADR signals that were missed by 
individual systems, a real-world challenge is about how to communicate the results with 
clinical assessors using this purely statistic based model. 
6.5 Future directions 
The research presented in this dissertation provides the initial attempt for developing a 
framework of integrating ADR evidence from multiple data streams. Future research can extend 
the current work in various directions. 
1. For the data, we know that data size and data quality are extremely important for 
detecting ADRs, for example, we did not observe the improvement when combining 
FAERS and an EHR from a single facility. Therefore, we plan to acquire more 
longitudinal information within a single EHR and collaborate with other facilities for 
acquiring more EHR data. The common data model developed by OMOP could be 
helpful for the integration of EHR data. 
2. Currently, the method involving signal calibration relies on the availability of reference 
negative controls. In the future, we plan to develop a theoretical null distribution to 
calibrate signal scores. In addition, the OMOP has a standard procedure for examining 
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and collecting negative controls for a particular ADR, which could be generalizable to 
other ADRs.  
3. The confounding adjustment method assumed a single and homogeneous odds ratio for a 
drug-ADR combination, which may not be appropriate. In future work, we plan to apply 
clustering algorithms to group patients with similar symptoms or diagnoses and then 
acquire associations within these relatively homogeneous patient groups. For this study, 
grouping patients based on their ICD-9 diagnosis codes could be a good start. 
4. The confounding method did not deal with drugs given only to a particular patient 
population and therefore the control groups on the basis of a general population were not 
representative for that population. In future work, we plan to analyze particular drug-
ADR combinations in the subgroup of general population such as elderly patients. In 
addition, we plan to introduce a knowledgebase involving drug indication information, 
and compare the studied drug with drugs having the same indication.   
5. A more prospective evaluation involving emerging ADR signals will be undertaken in the 
future using a time-indexed reference standard. 
6. The combined system could be extended to incorporate information from more than two 
data sources, for example, combining signals from the SRS, claims and EHR databases 
could be next steps. Another promising direction is discovering signals on the basis of a 
resource that is sensitive for ADR detection, and then re-ranking signals using a resource, 
which provides high precision. 
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6.6 Conclusions 
Completing safety profiles over the market life of a drug is a constant challenge in the field of 
pharmacovigilance and is critical for patient safety. The research presented in this dissertation 
has produced several novel findings that provide new insights that demonstrate that 
computationally integrate ADR evidence from multiple data streams has the potential to detect 
ADRs earlier. To the best of my knowledge, this is the first study integrating data from a SRS 
and EHR databases. In conclusion, this dissertation develops a combined system to synthesize 
evidence and a method to reduce confounding effect in both EHRs and SRSs, which could 
potentially unveil drug safety profiles and novel adverse events in a timely fashion.
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